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1  Introduction 
The hepatitis B virus (HBV) causes acute and chronic human liver infections. HBV 
infections are globally distributed as more than 350 million people are chronically infected 
with a mortality rate of approximately 1 million people per year. To date only interferone 
and nucleoside/nucleotide derivatives as reverse transcriptase inhibitors are approved by 
FDA for treatment of chronic hepatitis B virus infections (Conjeeveram and Lok, 2003). 
These agents can rarely achieve a sustained suppression of HBV replication and in many 
cases this approach leads to remission of liver disease. One major problem is that all 
available antiviral substances specific against HBV are against the same target, the viral 
reverse transcriptase. Therefore, new antiviral therapeutic agents directed against novel 
targets are required. 
HBV is the most prominent member of family Hepadnaviridae. The mature virus particle 
composed of a unique, incomplete, double stranded DNA genome packged into an 
icosahedral capsid which is surrounded by an envelope. The viral envelope carries three 
surface proteins which termed according to their size as large (L), middle (M) and small (S) 
surface proteins (Seeger and Mason, 2000). During HBV capsid envelopment, a specific, 
highly conserved domain (matrix binding domain, MBD) on the capsid surface binds to the 
matrix domain (MD) in the L surface protein. These two domains (MBD and MD) interact 
with each other specifically during virus budding (Bruss, 1997; Pairan and Bruss, 2009). 
Interfering with this interaction e.g. by a molecule binding to MBD on the capsid surface is 
a possible strategy for antiviral intervention.  
Aptamers are low molecular weight molecules, selected from a random library of nucleic 
acids (RNA or ssDNA). They can bind to target molecules e.g. proteins by a three 
dimensional (3D) recognition. The aim of this work was to select an aptamer with a high 
binding affinity to the MBD on HBV capsid surface. Such a molecule can potentially inhibit 
the specific MBD-MD interaction and consequently, abolishing the capsid envelopment. 
Thus, an aptamer with high binding affinity to MBD can be used as a starting point to develop 
a new antiviral agent against the HBV infection.  
In this study, a ssDNA aptamer with high binding affinity to the MBD on HBV capsid surface 
was selected showing inhibition of HBV secretion in cell culture.   
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2  Review of the literature 
2.1 Hepatitis B Virus 
2.1.1 History and taxonomy 
The hepatitis B virus (HBV) was the first virus among human hepatitis viruses from which 
the proteins and the genome were detected and characterized. By epidemiological 
observations, two types of hepatitis transmission were identified: type A which was 
transmitted by the faecal-oral route and type B which was transmitted parenterally (Findlay 
et al., 1938). An unknown antigen in the blood of an Australian aborigine (Australia 
antigen) was discovered by Blumberg and his colleagues and it was realized that the 
appearance of this antigen was tightly related to type B hepatitis (Blumberg et al., 1967). 
Three years later, Dane discovered in the serum of hepatitis B patients 42 nm large virus-
like particles (Dane particles) that carried this antigen on their surface, and these particles 
were considered to be the hepatitis B virus. In addition, 22 nm small spherical and 
filamentous particles were discovered and were then shown to be subviral particles (Dane et 
al., 1970). HBV infection was known to induce liver inflammation (Findlay et al., 1938). In 
1970, it was assumed from epidemiological data that HBV may induce liver cancer and this 
was augmented by the discovery of an HBV-like agent in woodchucks (marmot-like 
animals from North America), which had been observed to develop liver cancer (Summer et 
al., 1978).   
HBV is a member of the family Hepadnaviridae, its name derived from the hepatotropism 
and DNA genome (Howard, 1995). The family Hepadnaviridae comprises two main genera: 
genus Orthohepadnavirus (viruses infecting mammals) and genus Avihepadnavirus (viruses 
infecting birds) which are divided into species. The most prominent member of the genus 
Orthohepadnavirus is HBV while that of the genus Avihepadnavirus is the duck hepatitis B 
virus (DHBV). Variants of HBV can be currently classified into eight genotypes which 
involve 24 subgenotypes in-between. The genotypes were designed in an alphabetic manner 
A–H. The genetic divergence among A-E and G genotypes is around 8-9% while genotype 
F and its related genotype H are of higher sequence divergence (approximately 13%) 
(Norder et al., 2004; Schaefer, 2005; Arauz-Ruiz et al., 1997). New variable hybrid hepatitis 
B viruses can evolve by recombination between different parental genotypes (Norder et al., 
1996). 
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2.1.2 Epidemiology and pathogenesis 
HBV has a global high incidence rate. Out of more than 2 billion world-wide HBV infected 
people, 360 million individuals are chronically infected and act as carriers (Hollinger and 
Liang, 2001). Annually, more than 4 million individuals are newly infected by HBV, and 
nearly one million people die from chronic active hepatitis, cirrhosis or liver cancer (WHO, 
2001). HBV genotypes show some sort of specific geographical distributions: Genotype D 
appears to be globally distributed (Europe, Africa, and Asia). Genotype A is mainly present 
in central Africa, genotypes B and C in east and south-eastern Asia, genotype E in west, 
sub-saharan Africa and genotypes H and F are largely confined to aboriginal Indian 
populations in central and south America. Genotype G is mostly detected in co-infection 
with other HBV genotypes. Many epidemiological studies showed high incidences of 
hepatocellular carcinoma (HCC) in the HBV endemic regions. In addition, differences in the 
potential to cause HCC have been reported among HBV genotypes (Beasley, 1988; Tanaka 
et al., 2008). 
The incubation period of HBV is 120 days on average. HBV infection takes place either 
horizontally or vertically. The horizontal transmission occurs by direct contact with 
infectious blood or other body fluids. The prenatal HBV transmission showed the greatest 
risk for infants born to women who are HBeAg-positive and ranges from 70% to 90% at 6 
months of age. The iatrogenic transmission of HBV can also happen because the virus is 
stable on environmental surfaces for more than one week (Hoofnagle et al., 1978; Stevens et 
al., 1979; Bond et al., 1981).  
Most HBV infected persons develop a clinical or sub-clinical self-limiting acute hepatitis 
and within a few weeks post-infection spontaneous clearance of HBV-infected hepatocytes 
or suppression of viral expression takes place. However, some infected individuals develop 
chronic infection. Only 25-50% of cases of acute HBV infection are symptomatic; the 
remainder are asymptomatic. Following the incubation period, symptoms of the pre-icteric 
phase begin to appear. These symptoms include anorexia, nausea, vomiting, weakness and 
pain in the right upper body quarter. In addition, the hepatic transaminases reach a peak. 
Once the icteric phase (lasts nearly 3 weeks) starts these symptoms and the high levels of 
transaminases begin to decline. Following the symptomatic phase the convalescent phase 
starts and last for up to six months with nearly complete disappearance of symptoms (Alter, 
2003).  
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An HBV specific T cell response is considered the main factor affecting and modulating the 
virus pathogenesis. HBV variants may influence the course of disease and on the other hand 
they may counter act the efficacy of antiviral therapy (Rabe et al., 2003; Baumert et al., 
2007). 
Although there is no definite treatment for acute hepatitis B, some studies showed that high 
doses of lamivudine are recommended in patients with severe acute HBV infections to 
reduce the risk of progression to fulminant hepatitis (Lisotti et al., 2008). Some nucleoside 
or nucleotide analogues were approved by FDA for the treatment of chronic hepatitis B e.g. 
lamivudine, adefovir, entecavir and emtricitabine. These analogues are used alone or in 
combination with the immune modulator IFN-α (Conjeeveram and Lok, 2003). Strategies 
for immunization using hepatitis B vaccines were followed in most countries all over the 
world to prevent hepatitis B virus infection (Van Damme and Vorsters, 2002).  
2.1.3 Virion structure 
The blood of HBV-infected persons carries three types of virus-associated particles: mature 
virus particles and subviral particles (SVP) which involve HBsAg spheres and HBsAg 
filaments (Fig. 1). The virus appears under the electron microscope as a spherical double-
shelled structure with a diameter of 42–45 nm. The outer shell resembles the viral envelope 
and is formed by the envelope proteins together with the classical host lipid bilayers while 
the inner one is referred to as the core particle or capsid and is composed of capsid- or core 
protein (HBc protein). The viral capsid consist of 180 or 240 identical core proteins, which 
form capsids of 32 and 36 nm in diameters with a T=3 and T=4 symmetry, respectively. The 
virus capsid encloses ds/ss positive DNA genome linked covalently at its 5′ end with the 
viral polymerase (Crowther et al., 1994; Kenney et al., 1995). 
2.1.3.1 Protein composition of HBV particles 
The hepatitis B virus minus DNA strand contains 4 open reading frames (ORFs) which 
encode for seven proteins, 3 surface proteins (SHBs, MHBs and LHBs), the core protein 
(HBc), a secretory protein (HBe), the viral polymerase (P) and the X proteins. 
2.1.3.1.1 Surface proteins (HBs) 
The surface proteins (envelope proteins) are classified into 3 different proteins, small (S), 
middle (M) and large (L) protein and they are encoded by a single open reading frame (ORF 
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S) which is divided into the S gene, pres1 region and pres2 region (Heermann et al., 1984).  
The different HBV genotypes showed S gene and pres2 region of constant length, however 
the pres1 and pres2 regions show higher amino acid divergence than the S gene. 
The small hepatitis B surface protein (SHBs), encoded by the S gene is 226 amino acids 
long. This protein is one of the main constituents of all forms of HBV particles; it is 
synthesized by the virus in high quantities. SHBs has a conformational, highly antigenic 
epitope (HBsAg, Hepatitis B surface antigen) which is composed of the “a” determinant 
flanked by two mutual d/y determinants at the amino acid position 122 and w/r determinants 
at the position 160 (Bancroft et al., 1972; Torre and Naoumov, 1998). HBsAg “a” 
determinant has two-loop structure which protruded on the surface of the viral particles and 
its residues, aa 124-147, are relatively conserved in all HBV genotypes. The “a” 
determinant is directly involved in inducing neutralising antibodies. It forms the base of 
current HB vaccines (Chen and Oon, 1999; Bartholomeusz and Schaefer, 2004). At 
asparagine 146 of the S protein, there is a signal for the addition of an N-linked glycan 
which is present in approximately half of the SHBs molecules. Therefore, SHBs shows two 
different forms, an unglycosylated form of 24 KDa and a glycosylated form of 27 KDa 
molecular weight (Peterson, 1981). 
The middle hepatitis B surface protein (MHBs), encoded by the S gene and the pres2 
region (an additional 5′ open reading frame with 55 codons). The N terminal 55 amino 
acids domain is mostly hydrophilic and contains a dominant epitope located at the surface 
of the envelope (Tiollais et al., 1985). In addition to the first glycosylation site of the S 
protein at as asparagine 146, there is a second glycosylation site at asparagine 4 of the 
preS2 domain. Therefore, MHBs can be synthesized into 3 different forms: as an 
unglycosylated protein of 30 KDa, a single glycosylated protein with a glycan residue at 
asparagine 4 of 33 KDa and double glycosylated protein of 36 KDa (Heermann et al., 
1987; Mehta et al., 1997).  
The large hepatitis B surface protein (LHBs) is encoded by the pres1 domain in addition to 
the pres2 and S domains. The preS1 domain encodes for 108 or 119 aa. Overexpression of 
LHBs alone results in the retention of the protein in the ER, which may lead to the 
development of hepatocellular carcinoma (Chen and Oon, 1999). LHBs is 
monoglycosylated although it contains a second glycosylation site at aa 4 of the PreS2 
region so; LHBs can be synthesized into two different forms: an unglycosylated protein of 
39 KDa and a glycosylated protein of 42 KDa (Heermann et al., 1987; Hildt et al., 1996). 
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Fig. 1. Morphology and structure of HB associated particles. (A) Schematic diagram of 
HBV particle. The HBV particle is composed of a 3.2 kb partially ds DNA which is 
covalently linked by its 5’ end to the DNA polymerase and encapsidated by a capsid 
composed of 180-240 core proteins. This capsid is surrounded by an envelope carrying 
small, middle and large surface proteins (HBs). The three envelope proteins contain an 
identical S domain. MHBs contains the additional pre-S2 domain while LHBs contains the 
additional pre-S1 domain together with the pre-S2 domain. (B) Schematic diagram of 
subviral particles. The subviral particles consist of the same proteins as the virion envelope 
but the spheres contain fewer LHBs.  
 
 
 
 
 
 
 
 
 
 
 
2.1.3.1.2 Transmembrane topology of the surface proteins 
The surface proteins are synthesized at the ER and show a complex transmembrane topology 
(Bruss, 2004) (Fig. 2). The N and C termini of S protein are disposed externally in the mature 
particles (luminal disposition) of both.  Therefore, the protein traverses the ER membrane at 
least twice. The ER membrane insertion takes place by two N terminal domains, aa 11-28 
(TM1, transmembrane domain 1) and aa 80-98 (TM2, transmembrane domain 2), which are 
spaced by a hydrophilic region exposed internally in the mature particle (cytoplasmic 
disposition) (Eble et al., 1987; Bruss and Ganem, 199lb). There is a second hydrophilic loop, 
aa 99-168 aa, exposed on the luminal side which carries the major epitope and the 
glycosylation site (Stirk et al., 1992). The C terminal region of the S protein is hydrophobic 
and may contain another two transmembrane domains (TM3and TM4) (Eble et al., 1986). 
The M and S proteins have an identical topology as the hydrophilic preS region of M and the 
preS-specific epitopes protrude on the surface of the mature particles (Kuroki et al., 1990; 
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Heermann and Gerlich, 1991).  The preS2 region of M protein shows luminal disposition and 
this was augmented by its glycosylation (Heermann et al., 1984).  
The topology of L protein shows some alterations relative to the S and M proteins. The preS1 
and preS2 domains of the L protein are initially disposed on the cytosolic side of the ER (i-
preS; internal preS). This explains the partial glycosylation of asparagine 146 in the S domain 
but not of asparagine 4 located in preS2. However, around 50% of L protein in mature 
particles shows a contrary topology with the preS1 and preS2 domains which protruding on 
the surface of the mature particles (e-preS; external preS) (Bruss et al., 1994; Bruss and 
Vieluf, 1995; Prange and Streek, 1995). The L protein shows myristoylation at glycine 2 
which seems to be essential for viral infectivity (Persing et al., 1987; Gripon et al., 1995; 
Bruss et al., 1996). 
Fig. 2. Transmembrane topology of the HBV surface proteins. The S protein (black line) 
containing TM1 (yellow barrel) and TM2 (orange barrel). The M protein consisting of S and the 
preS2 domain (dark blue line). The L protein carries the additional preS1 domain (cyan line). Black 
and dark blue bars indicate glycosylation sites while the cyan dot resembles the myristoylation of L 
(Schittl, 2012). 
2.1.3.1.3 Core protein (HBc) 
The HBc protein is the major component of the nucleocapsid shell. HBc is either 183 or 185 
amino acids long depending on the genotype of the virus and its molecular weight is 21 
KDa. It is expressed in the cytosol of the infected hepatocytes. It packages its own mRNA 
and the viral polymerase after formation of the RNA-polymerase complex and assembles 
into core particles (Ou et al., 1986; Nassal et al., 1992).  
The core protein involves two different domains, the N-terminal 144 aa domain and the C-
terminal arginine rich domain. The N-terminal 144 aa domain is essential for capsid 
formation. Cryo-electron microscopy and crystallization reveals that the N-terminal domain 
builds up five α−helices arranged in an anti-parallel orientation forming a spike between α3 
and α4 (Conway et al., 1997; Wynee et al., 1999). The C-terminal arginine rich domain is a 
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multifunctional domain. It is essential for RNA packaging and it syntheses the viral positive 
DNA strand (Hatton et al., 1992).  
The HBV capsid is constructed from 180 or 240 copies of the core protein. Assembly of a 
core particle is initiated by formation of a core protein dimer (Fig. 3A) which rapidly 
assemble to the icosahedral capsids with a T=3 or – more frequently – T=4 symmetry (Fig. 
3B) (Endres and Zlotnick, 2002; Roseman et al., 2005). The HBV capsid is not a completely 
closed protein shell; it shows holes of nearly 2 nm diameter. These capsid holes allow the 
nucleotides which are required for DNA synthesis of a mature viral genome to enter the 
lumen. During the maturation of the viral genome, these holes were thought to undergo 
conformational changes thereby exposing the C terminus of the C protein on the capsid 
surface facilitating the transport of the viral DNA into the nucleus (Kenney et al., 1995; 
Kann et al., 1999). 
The expression of HBV core protein and its mutants can be carried out in heterologous 
systems, e.g.  Escherichia coli. The expressed core proteins assemble into capsids even in 
the absence of the viral genome and it has been shown that the first 144 amino acids of the 
core protein are sufficient for assembly (Birnbaum and Nassal, 1990). It was assumed that 
HBV capsids that are assembled in E. coli have the same morphology as authentic capsids 
from virions of infected liver (Kenney et al., 1995). 
In chronic hepatitis B, the HBc protein considered the major target of the host immune 
response and it contains several immunodominant epitopes which assist in the evolution of 
escape mutants (Kao, 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Morphology of HBV capsid and the core homodimer. (A) Sphere model of a HBV core 
homodimer showing the amino acid residues important for capsid envelopment (black spheres) 
(from Pairan and Bruss, 2009). (B) External cryo-electron micrograph of T=4 symmetrically 
assembled HBV capsid (from Conway et al., 1997).  
 
   
(A) (B) 
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2.1.3.1.4 HBe protein 
The HBe protein is a secretory form of the HBc protein. It is a non-structural protein that 
shares about 90% of its amino acids with the HBc protein. The pre-C sequence at the 5′ 
terminal part of ORF C encodes for a hydrophobic α-helix, which is a secretion signal cleaved 
off by a signal peptidase, and prevents the folding of the HBe protein similar to HBc protein. 
It is essential for the translation/translocation of HBe into the lumen of the endoplasmic 
reticulumn and the release of HBe into the circulation of the infected patient. Although HBe 
and HBc proteins have nearly identical amino acid sequences but there is little antigenic 
homology between them because of the differences in their folding (Bruss and Gerlich, 1988; 
Bruss and Ganem, 1991; Wasenauer et al., 1992). 
2.1.3.1.5 Hepatitis B polymerase (P) protein 
The P protein is a 90-kDa protein, the largest protein among the HBV proteins, is encoded by 
the ORF P (Bartenschlager et al., 1992). The ORF P has several functions in HBV replication, 
such as RNA pregenome (pgRNA) encapsidation, priming of DNA synthesis, reverse 
transcription, and (+) strand DNA-polymerisation (Burda et al., 2001). The HBV polymerase 
is composed of four distinct domains: an N-terminal domain (TP) that serves as the primer for 
the reverse transcription, a spacer region of unknown function, reverse transcriptase 
(RT)/polymerase domain and ribonuclease H (RNase H). The TP domain linked to the 5′ end 
of the minus-strand of the genome is also termed primase as it is essential for the priming of 
minus-strand synthesis (Bartenschlager and Schaller, 1988). The reverse transcriptase 
(RT)/polymerase domain is multifunctional, it is responsible for the synthesis of minus strand 
DNA from pgRNA by reverse transcription, builds the plus DNA strand by its polymerase 
function (Köck et al., 2003). The RT/polymerase domain is assumed to have a structure 
similar to the RT of retroviruses with fingers of a palm (Beck et al., 2002; Torresi et al., 
2002). The RNase H domain cleaves and degrades the RNA if it is present in hybrids of 
RNA and DNA.  
2.1.3.1.6 Hepatitis B x protein (HBx) 
The X protein is encoded by the ORF X, the smallest ORF in the HBV genome. It is 
composed of 154 amino acids with a molecular weight of 17 KDa. HBx protein is present 
only in orthohepadnaviruses and not in avihepadnaviruses. The HBx protein function is still 
not fully understood, but it is assumed that it inhibits the viral protein degradation inside the 
host cell (Chen and Oon, 1999) and plays a role in hepatocarcinogenesis (Kew, 2011).  
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Fig. 4. HBV DNA genome showing the circular arrangement of the four overlapping but 
frame-shifted open reading frames. The partially double stranded DNA genome (thick black 
lines) contains four overlapping open reading frames (ORF C: green; ORF S: red; ORF P: blue 
and ORF X: white). The minus strand bound covalently to the endogenous polymerase (yellow 
oval) at the 5′ end. A small RNA primer (grey line) located at the 5′ end of the positive strand. 
The orange boxes refer to the direct repeats DR1 and DR2. The outer cyan circle refers to the 
posttranscriptional pregenomic RNA which involves the epsilon signal at its 5′ end (Schittl, 
2012). 
 
   
2.1.3.2 HBV genome 
The DNA of HBV appears under the electron microscope, compact, circular and partially 
double stranded and it is of 3.2 kb long (Robinson et al., 1974). In HBV virions the genome 
has an incomplete plus-strand with defined 5′ end but a variable 3′ end and a complete 
minus-strand, the coding strand, which has defined 5′ and 3′ ends. The viral polymerase is 
covalently bound to the 5′ end of the minus strand while the 5′ end of the plus-DNA strand 
is capped by an 18 base long oligoribonucleotide, which serves as a primer. The minus-
strand has terminal redundant sequences of 8–9 bases in its both ends, resulting in a region 
in which the genome is triple-stranded (Will et al., 1987). There are two short direct repeats 
of 11 nucleotides length (DR1 and DR2) present at the 3’ end of the negative and the 5′ end 
of the plus strand, respectively (Fig. 4). 
All genomes of mammalian hepadnaviruses contain four partially-overlapping ORFs, which 
are encoded by the same minus-DNA strand. These four ORFs (ORF S, ORF P, ORF C and 
ORF X) code for in total 7 proteins, ORF S which encodes the large, middle and small 
envelope proteins is completely located within the ORF P which encodes the DNA 
polymerase, ORF C which encodes the HBc and HBe proteins and ORF X which encodes 
the HBx protein overlap partially with ORF P (Fig. 4). 
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2.1.4 HBV life cycle 
The HBV life cycle (Fig. 5A) starts with the attachment of the virion by its envelope to a 
hepatocytes surface receptor. Recently, it was identified that sodium taurocholate 
cotransporting polypeptide (NTCP) which is mainly expressed in the liver, is a functional 
receptor for HBV and HDV (Yan et al., 2012). Primary hepatocytes are the first cells used 
as infectivity systems for HBV. Although many cell lines, e.g. HepG2 and HuH 7 cell lines 
are permissive for HBV replication after transfection but they are not susceptible to HBV 
infection and this was owed to this phenomenon is caused by an ongoing de-differention 
process which blocks the virus uptake by cells and this was augmented by the loss of 
susceptibility of all primary hepatocytes to their corresponding virus within a few days after 
they are taken into culture. Gripon and his colleagues had established a new cell line called 
HepaRG supported HBV infection comparable to PHH (Gripon et al., 2002). 
Once the capsid enters the hepatocyte, it is transported to the nucleus by the assistance of 
the nuclear localization signal at the C terminus of the core protein. Inside the nucleus, the 
remaining gap of HBV plus-DNA strand is filled by the celluar polymerase (Summers et al., 
1975; Landers et al., 1977) and then the viral genome is converted to a covalently closed 
circular DNA (cccDNA) which undergoes transcription to continue the viral replication. 
The cccDNA serves as the template for synthesis of five viral transcripts (mRNAs) by the 
action of cellular RNA polymerase II. There are two mRNAs of approximately 3.5 kb long,  
one serves the translation of the precore secretory protein (HBe) and the other is the pgRNA 
which encodes for the nucleocapsid protein and the polymerase/RT protein. There are 2.4 
and 2.1 kb mRNAs encoding the surface proteins (HBs, MHBs and LHBs) and a 0.9 kb 
mRNA encoding the X protein. The pgRNA is packaged with the polymerase/RT protein by 
its encapsidation signal at the 5′ ε-stem loop, into core particles and then reverse transcribed 
by the polymerase into progeny HBV DNA (Tavis and Ganem, 1996; Günther et al., 1997; 
Kann et al., 1999).  
During the reverse transcription of the pgRNA into the (-) DNA strand by the endogenous 
polymerase, the pgRNA template is degraded by the HBV polymerase RNase H activity 
leaving a small segment. This segment of RNA is composed of the 5′ Direct Repeat 1 region 
(DR1) which is translocated and anneales to the 3' direct repeat 2 region (DR2). This RNA 
oligomer is used as a primer for the synthesis of (+) DNA. The (+) DNA synthesis is then 
continued by the polymerase. The short terminal redundancy (r) on the negative strand is 
also copied forming the 5′ r. The new mature viral nucleocapsids transfer to the ER, where 
they are associated with the envelope proteins that have previously been inserted as integral 
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membrane proteins into the lipid membrane of the ER and finally the newly formed virions 
bud into the lumen of the ER, from which they are secreted via the Golgi apparatus out of 
the cell (Lien et al., 1986; Mahoney and Kane, 1999).  
The sera of highly viraemic HBV carriers contain huge amounts of non-infectious subviral 
particles (SVP) composed of excessive HBs protein (HBsAg). Most of these are spherical 
particles of 17–25 nm, which are secreted in 100–10000-fold excess over virions. The 
subviral particles have neither capsid nor HBV DNA and thus they are non infectious. The 
different subviral particles conformations contain different ratios of S/L HBs. The 
filamentous form is correlated with a higher concentration of the L protein (Heermann et al., 
1984). The formation and assembly of subviral particles take place in a post-ER pre-Golgi 
compartment (Simon et al., 1988). 
2.1.5 Envelopment of core particles  
Only mature capsid can undergo envelopment while immature ones containing pgRNA can 
not be enveloped. It is assumed that the synthesis of the minus DNA changes the 
conformation of the nucleocapsid exposing a specific signal which is essential for capsid 
envelopment. The matrix binding domain (MBD) is a specific domain located at the base of 
the spike and in the groove between capsid spikes having an important role in HBV 
assembly. The introduction of point mutations in this domain e.g. I126, K96, L95 and S17 
(Fig. 3A) allows capsid assembly but results in the inhibition of capsid envelopment. 
Mutations at the tip or stem of the capsid spike had no impact on the envelopement process 
(Ponsel and Bruss, 2003; Parian and Bruss, 2009). 
The viral envelope proteins, especially L protein, are considered to play a key role in the 
envelopment of HBV capsids (Bruss and Ganem, 1991). A smaller domain between aa 103 
and 124 in the cytosolic portion of L protein plays an essential role in HBV nucleocapsid 
envelopment so, it was termed as the matrix domain (MD) (Bruss, 1997). Furthermore, the 
minimal distance between this domain and TM1 was determined to be 26 amino acids 
which would fit well to the length of the capsid spike (Le Seyec et al., 1998; Kluge et al., 
2005). In vitro binding assays using peptides corresponding to the MD of L protein revealed 
also a direct interaction between MD of L protein and the MBD on the capsid surface (Fig. 
5B) (Poisson et al., 1997). Both, HBV capsids and L protein have the ability to bind to γ2-
adaptin, a protein important in the ESCRT-mediated multivesicular body (MVB) / lysosome 
sorting pathway. The core protein amino acid residue K96 was also shown to be essential 
for the recognition of γ2-adaptin (Hartmann-Stühler and Prange, 2001; Rost et al., 2006; 
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Döring et al., 2010). The budding site of HBV virions is still not clear but it was observed 
that the induction of mutations in the endosomal sorting complex (ESCRT-complex) 
inhibits virion release (Lambert and Prange, 2007). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. Life cycle and envelopment process of HBV. (A) HBV binds to the surface of hepatocytes 
and enters the cells with the help of its envelope proteins (receptor mediated endocytosis). Inside the 
cell, the capsid is transported to the nucleus where the partially circular DNA is converted to 
covalently close circular DNA (cccDNA). HBV cccDNA serves as a template for transcription of 
mRNAs and the pgRNA. The pgRNA is then encapsidated into core proteins and reverse-
transcribed. The core particles with the newly synthesised partially-circular genomes are finally 
packaged into viral envelopes in the ER, and then exocytosed with the synthesized subviral particles 
out of the cell. (B) X-ray crystal model of HBV virion showing an interaction between specific core 
residues (green spheres) with the interior loop of the L protein but without penetration of the capsid 
spike into the envelope (Dryden et al., 2006). 
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2.2 Aptamers  
2.2.1 Nature and theory  
The term aptamer is derived from the Latin word “aptus”– which means fitting and the Greak 
word “meros” – which means particle. Aptamers are short nucleic acids or peptides with a 
specific and complex three–dimensional (3D) shape characterized by stems, loops, bulges, 
hairpins, pseudoknots, triplexes, and/or quadruplexes. Based on their 3D structure, aptamers can 
bind to a wide variety of targets. Binding of the aptamer to the target molecule results from 
structure compatibility: stacking of aromatic rings, electrostatic and van der Waals interactions, 
hydrogen bindings, or from a combination of these effects (Ellington and Szostak, 1990; 
Hermann and Patel, 2000, Feng and Hu, 2008).   
In 1990, screening and selection of RNAs libraries against T4 DNA polymerase and many 
organic dyes were achieved. Ellington and Szostak called the selected RNA ligands as aptamers 
while the selection process was termed by Tuerk and Gold as SELEX (Systematic Evolution of 
Ligands by EXponential enrichment) (Ellington and Szostak, 1990; Tuerk and Gold, 1990).  
Aptamers are high-affinity and high-specificity ligands and they are mostly acting as 
inhibitors as they often bind to the functionally important parts of their targets (Eaton et al., 
1995; Proske et al., 2005) 
SELEX is a process involving the progressive purification from a random library of 
nucleic acid molecules or peptides (aptamers) with a high affinity for a particular target by 
repeated rounds of partitioning and amplification (Gopinath, 2007). Briefly, randomized 
pools of RNA, ssDNA or peptides are incubated with target molecules under specific 
selection conditions. The bounded aptamers are partitioned away from non-binders, 
amplified to generate a new pool, and the process is repeated until sequences with suitable 
phenotypes are obtained or until sequence diversity is greatly reduced (Hermann and 
Patel, 2000). 
2.2.2 Technology  
2.2.2.1 Oligonucleotide library 
The starting point of a SELEX process is a chemically synthesized random oligonucleotide 
library. Libraries containing a random region of maximal 20-60 nt in length and flanked at 
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its both ends by two fixed sequences for PCR fragments amplification are used (Conrad et 
al., 1996).  
Both RNA and ssDNA libraries are used in SELEX procedures. In principal, the affinity or 
specificity of ssDNA aptamers and RNA ligands is not different. The advantage of RNA 
aptamers is that they can be expressed inside of cells, which may be of great importance in 
experiments in vivo. On the other hand, DNA aptamers show higher stability and their 
selection is simpler and faster. Owing to this, during recent years DNA aptamers have become 
more and more widespread (Breaker, 1997). 
For the synthesis of the random region in ssDNA library, a mixture of all four 
deoxyribonucleotide derivatives is added to the reaction mixture allowing the random 
incorporation of a nucleotide into the growing molecule. To obtain an RNA library, the 
promoter sequence for the RNA polymerase of bacteriophage T7 is introduced into the 5′ 
terminal region of the ssDNA library, dsDNA is obtained by a polymerase chain reaction 
(PCR), and then an in vitro transcription is carried out. The synthesis of random sequences 
is relatively cheap. The obtained sequences depend on the ratio of the four nucleotides 
used which differs according to the manufacture process (Famulok and Mayer, 1999; 
Kulbachinskiy, 2007). 
Concerning the arrangement and type of randomization, different types of nucleic acid 
libraries can be used in SELEX, classical libraries (Tuerk et al., 1992; Burke et al., 1996), 
structurally constrained libraries (Biroccio et al., 2002; Hamm et al., 2002), libraries on the 
basis of a known sequence (Hirao et al., 2004), libraries free of fixed sequences (Vater and 
Klussmann, 2003), and libraries on the basis of genomic sequences (Shtatland et al., 2000). 
The complexity of the library can be determined easily as 4
n
 (n is the number of positions in 
the random sequence). For example, the complexity of a library with twenty five randomized 
nucleotides is 4
25 
or approximately 10
15
. 
Aptamers with chemically modified nucleotides can be used for achieving special purposes, to 
magnify the potential variety of oligonucleotides, to introduce new features e.g. functional 
groups providing new possibilities for the interaction with target molecules, to improve the 
stability of the aptamers or to increase their resistance to nucleases (Eaton et al., 1995; Kusser, 
2000). There are two standard approaches for obtaining chemically modified aptamers: the first 
approach is by using modified oligonucleotides directly during the selection. However, a 
problem might be that the ability of the nucleotide to serve as a substrate for RNA or DNA 
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polymerase is influenced. In the second approach, the already selected aptamers are modified 
but these post-selection modifications may result in lower affinity to their targets 
(Kulbachinskiy, 2007). There are different techniques for obtaining modified aptamers: (1) To 
improve the aptamer stability and their nuclease resistance, F or NH2 group can be introduced 
in the 2´-position of ribose (Jayasena, 1999; Nimjee, 2005) or by creating spiegelmers using 
aptamers composed of natural D–oligonucleotides which can be selected against mirror image 
targets, such as D–amino acid peptides, rather than natural L–amino acid peptides. After the 
isolation of the aptamer they can be chemically synthesized as L–oligonucleotide 
(Spiegelmer) and will bind to the natural L–amino acid peptide targets (Klussmann et al., 
1996; Nolte et al., 1996). (2) To improve the affinity and the specificity of the aptamers to 
their protein target, modified oligonucleotides (photoaptamers) containing functional groups 
that can be activated upon irradiation (such as 5-iodo-, 5-bromo-, and 4-thiouridine) forming 
covalent cross-links with their protein target can be used (Jensen et al., 1995). (3) To analyze 
the binding of the aptamers to their target protein, modified aptamers containing fluorescent 
groups can be used (Nutiu, 2005). 
2.2.2.2 Standard Selection Process (SELEX)  
The scheme of the standard SELEX procedure (Fig. 6) starts with the incubation of the 
oligonucleotide library with the target molecule. Then the selection step is carried out by the 
separation of bound oligonucleotides from those that are not bound. Selected oligonucleotides 
are then amplified. The amplification is performed by PCR in the case of DNA, and by RT-
PCR followed by in vitro transcription in the case of RNA. One cycle of target binding, 
selection and amplification is called a SELEX round. The SELEX rounds are repeated several 
times, and some of the oligonucleotides selected in the final round of the experiment are 
sequenced and evaluated. 
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Fig. 6. General scheme of the standard SELEX procedure. A library of DNA or RNA molecules 
is incubated with the target molecule, and the bound ones are separated from the rest. The sequences 
with affinity for the target are subsequently amplified to generate a pool of molecules that bind to the 
protein of interest. After several rounds, aptamers with high affinity and specificity can be selected. 
http://www.cd-genomics.com/Aptamers/SELEX.htm. 
 
   
 
 
 
 
 
 
 
 
 
The partitioning of the aptamer–target complex from non specific molecules can be achieved 
by various techniques. The most commonly used method for protein targets partitioning is 
filteration through nitrocellulose filters (Tracy and Kowalczykowshi, 1996; Bianchini et al., 
2001). The selection processes using nitrocellulose membranes usually require up to 12-15 
selection cycles. Alternatively, the use of functionalized magnetic adsorbent particles with a 
magnetic separation system has also been considered to be a useful tool for the separation of 
protein and nucleic acids (Gopinath, 2007). Also, using affinity tags like glutathione S-
transferase and streptavidin-derivitized surfaces (Dobbelstein and Shenk, 1995; Cox and 
Ellington, 2001) or column matrices like sepharose (Ciesiolka et al., 1995) can be used to 
reduce the number of required selection cycles. A counter–selection against the partitioning 
matrix is a very important step to avoid the isolation of sequences that have affinity to the 
matrix (Gold, 1995). During recent years, more effective separation methods are reported, e.g. 
Capillary Electrophoresis (CE), Flow Cytometry (FC) (Davis et al., 1997), Electrophoretic 
Mobility Shift Assay (EMSA) (Tsai and Reed, 1998), Surface Plasmon Resonance (SPR) 
(Misono and Kumar, 2005) or centrifugation (Rhie et al., 2003). 
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For the selection of RNA aptamers, the random DNA oligonucleotide library has to be 
transformed into a RNA library before starting the first round of a RNA SELEX process. A 
sense primer with an extension at the 5′ end containing T7 promoter sequence and an 
antisense primer are used to convert the ssDNA library into a double–stranded (dsDNA) 
library by PCR. The dsDNA is then in vitro transcribed by T7 RNA polymerase resulting in a 
randomized RNA library which can be used in SELEX. For further rounds of selection, the 
same procedures should be carried out after each round (Homann and Göringer, 1999).  
For the selection of DNA aptamers, the process is simpler than RNA SELEX as the library 
can be used directly in the first round of selection. The primer set derived from the fixed 
sequences at the 5′ and 3’end enable the amplification of the selected oligonucleotides in each 
SELEX round. After PCR amplification, a ssDNA preparation must be performed to generate 
a ssDNA pool for the next round. Many methods are used for ssDNA preparation e.g. (1) A 
biotin residue is introduced into one of the primers used for amplification and both DNA 
strands are separated under denaturing conditions either in a polyacrylamide gel after a pre-
incubation step with streptavidin or directly into a column containing streptavidin (Agratis, 
1996; Murphy et al., 2003). (2) An a symmetric PCR, in which one primer initiates DNA 
synthesis much more efficient than the other primer which is relatively unproductive, leading 
to the accumulation of ssDNA synthesized from the efficient primer (Ellington and Szostak, 
1992). (3) A hexaethyleneglycol (HEGL) spacer, a terminator for Taq polymerase, and a 
polyA tail are added at the 5′ end of the reverse primer. This leads to elongation of only one 
strand (–strand). Afterwards, the two strands can be separated according to their size using 
electrophoresis under denaturing conditions (Williams and Bartel, 1995). (4) A phosphate 
group is introduced into the 5′ end of one primer. Then the PCR amplified product is treated 
with the phage lambda exonuclease that digests the phosphorylated strand of DNA (Fitter and 
James, 2005).   
2.2.2.3 Site-directed selection of aptamers 
Complex target SELEX is a SELEX used for selection of aptamers against many 
heterogeneous targets, e.g. whole cells. It is used mostly to generate new biomarkers 
especially when biomarkers are not known in advance (Shamah et al., 2008). Aptamers 
against whole trypanosomes were successfully selected by this approach (Homann and 
Göringer, 1999). 
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There are many different methods can be used to avoid selection of aptamers to an 
undesirable epitope or to obtain ligands to a particular epitope of a protein target: (1) By the 
method of counter selection, aptamers are selected which interact with the full-size protein but 
do not bind to the mutant protein devoid of this epitope. The oligonucleotide library is firstly 
incubated with the whole protein target, and then oligonucleotides that do not interact with the 
mutant protein lacking the site of interest are selected (Andreola et al., 2001). (2) The method 
of competitive elution of aptamers using another ligand binding in the same site of the protein 
(Hale and Schimmel, 1996; Bridonneau et al., 1999). (3) Method of blended selection, uses 
oligonucleotides carry a known ligand specific for this protein. So, the selected aptamers can 
interact with a site near the binding site of this ligand (Charlton et al., 1997). (4) Aptamers 
can be selected against a peptide corresponding to any epitope of protein target. The selected 
aptamers can consequently recognize this epitope within the full-size protein (Bianchini et al., 
2001). (5) For the selection of aptamers using the anti-idiotypic approach, the first stage 
antibodies specific for a protein partner of the target protein are generated while in the second 
stage, aptamers interacting with the obtained antibodies are selected. Consequently, the 
selected aptamers will have affinity to the target protein (Hamm et al., 2002).  
2.2.2.4 Automated aptamer selection  
The traditional methods of aptamers selection are time consuming and laborious. Many attempts 
for automating in vitro selection of aptamers have been done successfully. E.g. Cox and 
colleagues used a system based on an augmented Beckmann Biomek 2000 Pipetting robot which 
was adapted to select aptamers against a protein by some modification and generated aptamers to 
hen egg white lysozyme. This robotic work station can carry out eight selections in parallel and 
will complete 12 rounds of selection in two days (Cox and Ellington, 2001).  
2.2.3 Aptamers and antibodies 
Aptamers have several properties which make them mostly override antibodies and in 
addition, potential attractive therapeutic agents (Rusconi et al., 2002). Aptamers, like 
antibodies, bind to their targets by three dimensional (3D) recognition. Aptamers 
characterized by their high specificity and high affinity to their targets as antibodies with Kds 
in the low picomolar to low nanomolar range. Aptamers are more stable, especially DNA 
aptamer, than antibodies and display lower or no immunogenicity (Eyetech Study Group, 
2003). In comparison with the antibody technology, aptamer research is still new but 
promising and its progress is fast.  
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2.2.4 Aptamers in Diagnostics  
2.2.4.1 Aptasensors 
Aptasensors are recognitive biosensor elements. Their main structural component is the 
aptamer (O’Sullivan, 2002). Aptamers can be chemically modified without influencing 
their affinity to incorporate particular reporters and also they can easily be labelled to be 
used in diagnostics (Balamurugan et al., 2008; Ulrich and Wrenger, 2009). Aptasensors 
can be classified into two main types, optical and electrochemical aptasensors, (1) Optical 
aptasensors include aptamers labelled with fluorescence, luminophore, enzyme, 
nanoparticles or aptamer with label-free detection systems (e.g., SPR, surface plasmon 
resonance) (Sassolas et al., 2011). E.g. an RNA aptamer was selected and used as a detector 
ligand in a sandwich assay to recognize vesicular endothelial growth factor (VEGF) (Drolet et 
al., 1996). (2) Electrochemical aptasensors depend on the immobilization of the aptamer on 
an electrode surface. Then the binding conditions with their targets can be monitored by 
the electrochemical current variations (Willner and Zayats, 2007). E.g. a novel 
electrochemical sensor system based on two different aptamers recognizing different epitopes of 
thrombin was developed. The first aptamer was thiol–modified and immobilized on a gold 
electrode for capturing thrombin while the second indicator aptamer was labelled with a 
pyrroloquinoline quinone glucose dehydrogenase (Ikebukuro et al., 2005).  
Several aptasensors have been developed to detect microorganisms and viral proteins e.g. 
RNA aptamer chip was successfully manufactured for detecting HCV core antigen (Lee et 
al., 2007) and also RNA aptamer developed for the detection of the HIV-1 Tat protein 
(Tombelli et al., 2005).  
2.2.4.2 Flow cytometry 
The binding of aptamers to their target proteins presented on either cell surfaces or 
microspheres can be detected by flow cytometry. E.g. a fluorescently labelled DNA aptamer 
with high affinity to human neutrophil elastase (HNE) was used to stain HNE-coated beads 
for flow cytometry (Lin et al., 1994; Davis et al., 1997) and also a fluorescently labelled RNA 
aptamer with a high binding affinity to mouse CD30 proteins had been evaluated for human 
CD30 protein recognition on intact cells by both, flow cytometry and fluorescence 
microscopy (Zhang et al., 2009). 
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2.2.5 Aptamers in therapeutics 
Aptamers have been proven to be a promising class of novel drug as they are characterized by 
small size, low or no immunogenicity, high stability, high specificity and high affinity to their 
targets. In addition, the synthesis and selection of aptamers is relatively easy and inexpensive. 
Aptamers have been validated as therapeutics in the areas of anti–infectives, anticoagulation, 
anti–inflammation, antiangiogenesis, antiproliferation, and immune therapy (Nimjee et al. 
2005). The first approval of an aptamer as a therapeutic agent was in 2004; Macugen 
(pegaptamib, by Pfizer and Eyetech) is the first aptamer drug approved by FDA against the 
age related macular degeneration, AMD (Ng et al. 2006). An anti–obesity drug was also 
produced by the NOXXON company, its active principle is spiegelmers which act against a 
hormone associated with an increase of appetite called ghrelin (Shearman et al. 2006). 
2.2.6 Aptamers against hepatitis viruses 
Butz and his colleagues selected a peptide aptamer, named C1-1, targeting the core protein of 
the hepatitis B virus (Butz et al., 2001). This aptamer was delivered in vitro and in vivo using 
adenoviral systems where it could inhibit viral DNA replication and consequently the viral 
infectious cycle (Zhang et al., 2009). An RNA aptamer with high affinity to hepatitis B virus 
surface antigen (HBsAg) has been successfully selected (Liu et al., 2010). The replication of 
HBV inside HepG2 cells has been inhibited by using an RNA aptamer which was selected 
against the ε RNA stem-loop on pgRNA (Feng et al., 2011). 
Aptamers have been selected against the NS3 protein of the hepatitis C virus (HCV) and 
showed in vitro inhibition of the viral protease activity by up to 90% (Urvil et al., 1997; 
Fukuda et al., 2000). The aptamer was then elongated at the 3’ end by a poly-14-U tail which 
showed binding affinity to the helicase portion of NS3. This longer version inhibited both, the 
proteinase and the helicase activity of NS3 (Kanai et al., 1995; Fukuda et al., 2004). Aptamers 
have also been selected against a conserved internal ribosome entry site (IRES) in the 5′ UTR 
of HCV (Kikuchi et al., 2003). High affinity ssDNA aptamers were successfully selected 
against the HCV envelope glycoprotein E2 which is proposed to be essential for viral 
attachment (Chen et al., 2009). 
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3  Objectives 
The goal of this research project was to select and characterize ssDNA aptamers specifically 
binding to the matrix binding domain (MBD) of HBV capsids, and to evaluate a potential in 
vitro inhibition of the capsid envelopment process by these aptamers which would be a 
potential therapeutic application. The MBD of the HBV capsid is extremely conserved and 
single amino acid substitutions usually block virion formation. The MBD mediates a very 
specific interaction with the matrix domain (MD) of L envelope protein of the virus and this 
interaction is essential for the envelopment process.  
Firstly, it was necessary to overexpress and purify HBV WT capsids carrying the native MBD 
as well as HBV I126A mutant capsids, a capsid variant with a single mutation in the MBD 
that blocks the envelopment process of HBV (Pairan and Bruss, 2009). Both capsid variants 
should be expressed in E. coli to be used as a target and counter target, respectively, in 
SELEX.  
Secondly, ssDNA aptamers against the MBD of the HBV capsid should be selected in vitro 
by SELEX with counter selection. After enrichment, the aptamers should be cloned and 
characterized.  
Thirdly, after the isolation and characterization of the selected aptamers, the structure of the 
aptamers should be characterized and the binding dissociation constants (Kd) should be 
measured. 
Finally, the inhibitory effect of selected aptamers on the HBV infectious cycle in HuH 7 cell 
culture should be determined. 
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4  Material and methods 
4.1 Material 
4.1.1 Antibodies 
Antibody Application Description Origin Provided by 
H800 Primary antibody 
Western blot & 
immunoprecipitation 
Polyclonal anti-
HBc antibodies 
Rabbit Heinz Schaller, 
university of 
Heidelberg  
Anti-rabbit Secondary antibody 
Western blot 
Horseradish 
peroxidase 
conjugated anti-
rabbit IgG 
antibody 
Goat Dianova, 
Hamburg 
Anti-HBS Immunoprecipitation Polyclonal 
serum 
Sheep W.Gerlich, 
Gießen 
 
4.1.2 Aptamers 
Type ssDNA  library 
Length   55-mer (with two fixed ends of 15-mer and random sequence of 25-mer) 
Complexity 10
15
 molecules 
Fixed sequence 5`GCGGGTCGACGTTTG……N (25)……CACATCCATGGGCGG´3 
Random 
sequence 
(N25) represents random oligonucleotides based on equal incorporation 
of A, G, C and T at each position. 
Provided by PURIMEX 
 
Negative aptamer 
(AO-0N) 
5`GCGGGTCGACGTTTGATATGTGGTATACGCTTGGGTGTTAC- 
ACATCCATGGGCGG´3 
 
4.1.3 Bacterial strains 
E.coli BL21 Star (DE3) pRARE2 RNaseE (rne 131) Mutant, with plasmid codons 
for argU, argW, AegX, GlyT, ileX, leuW, metT, 
proL, thrT, thrU, TyrU. 
ElectroMAX E.coli DH10B cells F¯, mcrA, Δ(mrr-hsdRMS-mcrBC), F80dlacZ 
ΔM15, ΔlacX74, endA1, recA1, deoR, Δ(ara, 
leu)7697, araD139, galU, galK, nudG, rps; 
provided by Life Technologies. 
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4.1.4 Bacterial media and antibiotics 
Product  Company Concentration 
LB medium Roth  
TB medium Roth  
2xYT medium Roth  
LB Agar Roth  
Ampicillin Sigma 100 µg /ml 
Canamycin  Sigma 50 mg /ml 
Chloramphenicol Sigma 33 mg /ml 
 
4.1.5 Capsids of HBV 
E. coli expressed C terminal deleted HBV 
capsid (its C protein of 149 aa) 
Dr.Tanja Bauer, Institute of Virology, Technical 
University  Munich (TUM). 
 
4.1.6 Cell line  
 
HuH7 
Human hepatoma cell line derived from the 
liver tumor of 57 years old Japanese 
(Nakabazashi et al., 1982). 
4.1.7 Cell culture media 
Product  Company 
DMEM Lonza 
Fetal bovine serum (FBS) Sigma 
MEM Non essential amino acids (NEAA) PAA 
Penicillin-Streptomycin (PS) PAA 
Sodium pyruvate PAA 
Trypsin/EDTA Biochrom AG 
 
4.1.8 Chemicals and Reagents 
Acrylamide mix (30%) National diagnostics 
Acetate Fluka 
Acetic acid Merck 
Ammonium acetate Sigma 
Ammonium persulfate (APS) Amersham Bioscience 
Ammonium sulfate Roth 
Bromophenolblue Sigma 
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Butanol Roth 
Canamycin disulfide Sigma 
Chloramphenicol Fluka  
Chloroform Roth 
Coomassie Brilliant Blue (R-250) Thermo Scientific 
Developer A Agfa Healthcare 
Developer B Agfa Healthcare 
Dimethyl Sulfoxide (DMSO) Sigma 
DL-Dithiothreitol (DTT) Sigma 
Ethanol Merck 
Ethidium bromide Sigma 
Ethyelene- Diamine –Tetra- Acetic acid (EDTA) Sigma  
Glucose Sigma 
Glycerin AppliChem 
Glycerol  Fluka 
Glycine Sigma 
Glycogen Fermentas 
Hydrochloric acid Sigma 
Isopropanol Merck 
Isopropyl-β-D-thiogalactopyranoside  Roth 
KH2PO4 Fluka 
KOH Fluka 
LE- Agarose Biozym  
LB-broth Base 20 g/l Gibco 
Magnesium acetate Sigma 
Magnesium chloride Fluka 
Methanol Merck 
Na2HPO4 Fluka 
NaCl Merck 
NaOH Roth 
Nonidet P40 (NP-40)  AppliChem 
Phenol-Chloroform-Isoamylalcohol Roth 
Polyethylenglycol (PEG 6000)  Merk 
Potassium acetate Fluka 
Rapid fixer Agfa Healthcare 
Skim milk powder Sigma 
Sodium acetate Sigma 
Sodium citrate dihydrate Sigma 
Sodium dodecyl sulfate (SDS) Fluka 
Streptavidin Thermo Scientific 
Sucrose Sigma 
Terrific Broth Medium  Roth 
Tetramethylethylendiamin (TEMED)  Biorad 
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Tris(hydroxymethyl) aminomethane Merck  
Tween 20 Sigma 
Urea Sigma 
Xylencyanol Sigma 
4.1.9 Enzymes 
4.1.9.1 Restriction enzymes 
Eco RI-HF New England Biolabs  
Eco RV New England Biolabs  
NcoI New England Biolabs 
Sal I-HF New England Biolabs 
4.1.9.2 Other enzymes 
CIP New England Biolabs 
DNaseI Qiagen 
Lysozyme Serva 
Proteinase K Applichem 
RNaseA Qiagen 
T4 DNA Ligase Fermentas 
 
4.1.10 Devices 
Acta Purifier (UV-900, pH/C-900, P-900) GE Healthcare 
Aspiration system Vacusafe and Vacuboy Integra Biosciences 
Balance 2200-2NM Kern&Sohn 
Biofuge fresco (small centrifuge) Heraeus, Thermo electron Corporation 
Biorad Mini Protean Tetra System Biorad 
CO2 incubator HERAcell 150i Thermo Scientific 
Deep freezer - 20 °C Liebherr 
Developer machine Curix 60 Agfa 
DISCOVERY Comfort mono-channel pippets Abimed 
Electroblot apparatus Biometra 
Electroporator E.coli Pulser Typ I Biorad 
Film cassette 18×24 Agfa  
Fine scale CP153 Sartorius 
Gel documentation Gel Doc Biorad 
Gene Amp PCR System 2700 Applied Biosystems 
Hybridisation glass tubes  Biometra 
Hybridisation oven Compact Line OV4  Biometra 
Incubator Memmert 
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Running chamber SDS OWI Separation Systems 
Labofuge 400 Heraeus 
Labogaz 206 Campingaz 
LightCycler 480 II Roche 
Magnetic stirrer Variomag  Neolab 
Megafuge 1.0 R Heraeus Instruments 
Microplate Reader Mode 550 Biorad 
Microscope Primo Vert Zeiss 
Microwave Siemens 
Millipore’s Amicon Ultra-2 filters (100K) Millipore corporation 
Millipore 30000 GE Heathcare 
Nanodrop ND 2000c Peqlab 
NanoVue 4282 V1.7.1 Spectrophotometer GE Healthcare  
Optima -80K Ultrazentrifuge  Beckman 
PD-Desalting Column  GE Healthcare 
Pipette  Abimed 
Power supply Model200/2.0 Biorad 
pH-Meter  inolab WTW 
Precision balance AC 100 Mettler 
Quartz cuvette Spectrophotometer Cell Micro Biorad 
Refractometer Krüss Optronic 
Refrigerator Liebherr 
Rotor JA 10 Beckman 
Rotor SLC 6000 Thermo Scientific 
Rotor SW28 Beckman 
Rotor SW55 Ti Beckman 
Safety bench Laminar Air HLB 2448 Heraeus 
Shaking incubator  Infors AG 
Sample rotator Fröbel 
Thermocycler Eppendorf 
Thermomixer comfort Eppendorf 
Thermomixer compact Eppendorf 
Transilluminator  Bachofer 
Ultra-centrifuge Beckman 
Ultra-temperature deep freeze (-80
o
C) Heraeus 
Vertical Polyacrylamide Gel Electrophoresis Biometra 
Vortexer MS3 basic IKA 
Water bath 37
o
C Köttermann 
Western blot developer machine Curix 60 Agfa 
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4.1.11 Kit systems 
AmpliTaq Gold DNA polymerase Applied Biosystems 
DC Protein Assay Biorad 
Fugene 6/ HD / Extreme Roche 
Lumi-Light Western Blotting Substrate Roche  
PCR Mastermix  Promega  
Protein G PLUS Agarose Santa Cruz Biotechnologies 
SYBRGreen I Master Roche 
QIAEX II Gel Extraction Kit Qiagen 
QIAquick Gel Extraction Kit Qiagen 
QIAquick PCR Purification Kit Qiagen 
4.1.12 Laboratory consumables 
6-well cell culture dish Nunc 
10 cm cell culture dish Nunc 
Cellstar tubes 15 ml and 50 ml Greiner bio-one 
Cryotubes Nunc 
Culture tube polypropylene round-bottom 14 ml Falcon 
Fitler papers Whatman 
Gel Tip 100 ART Molecular Bio Products 
Gene Pulser / E. coli Cuvette Biorad 
Gloves Gentle Skin Aloecare Meditrade 
Gloves Purple-Nitrile powder free Kimtech 
LightCycler 480 Multiwell Plate 96 Roche 
LightCycler 480 Sealing Foil Roche 
Petri dishes Greiner bio-one 
Pipette tips 10 µl, 200 µl and 1000 µl Tip-One SteriLab 
Plastic pipettes 5 ml, 10 ml, 25 ml and 50 ml Greiner bio-one 
Plastic cuvettes Braun 
Quali-PCR tubes Kisker 
Silanized Glass Wool PerkinElmer 
Sterile filter (0.22 µm) Millipore 
Syringes Becton-Dickinson 
Trans-Blot Pure Nitrocellulose Membrane (0.45 µm) Biorad 
Tubes 1.5 and 2 ml Eppendorf 
  
4.1.13 DNA and protein markers 
λ DNA/Eco911 Marker (BstEII) (Fig. 7A) Fermentas 
Gene Ruler 100 bp DNA Ladder (Fig. 7B) Fermentas 
Gene Ruler 10 bp DNA Ladder (Fig. 7C) Invitrogen 
Page Ruler Prestained Protein Ladder (Fig. 8A) Fermentas 
Page Ruler Plus Prestained Protein Ladder (Fig. 8B) Fermentas 
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Fig. 7: DNA ladders (A) λ DNA/Eco911 Marker (BstEII), Fermentas (B) Gene Ruler 100 bp, 
Fermentas (C) Gene Ruler 10 bp, Invitrogen  
 
 
  
 
 
Fig. 8: Protein ladders (A) Page Ruler, Fermentas (B) Page Ruler Plus, Fermentas   
4.1.14 Plasmids 
Plasmid Purpose Figure 
pETM13 Vector for HBV-WT and mutant capsid expression figure 9  
pBluescript II  KS (+) Vector for aptamers’ sequencing figure 10 
pRVHBV 
+ 
HBV-WT genome figure 11 
pSVHBV 1.1LE- HBV nucleocapsid production in HuH7 cells figure 12 
pSVHBV1.1LE-I126A HBV- I126A mutant capsid expression figure 13 
pSV45-57 HBV envelope protein production in HuH7 cells figure 14 
pSVBX24H HBV small envelope protein production in HuH7 cells figure 15 
1 µg/lane; 3% Agarose in 1X TBE stained with ethidium bromide 
10 bp DNA Ladder 
 
 
 
 
 
 
 
 
 
 
 
 
1 µg/lane; 3% Agarose in 1X TBE 
stained with ethidium bromide 
(A) (B) (C) 
(A) (B) 
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 Fig. 9: pETM13 (EMBL) 
Expression vector with Lac 
repressor (lacI), a canamycin 
resistant gene and the both 
replication origins (f1 origin, 
Origin). The actin binding domain 
(ABD) gene is a stuffer gene. It was 
replaced in the work by the 
sequence encoding the C-terminal 
deleted WT and I126A mutant HBV 
core protein.  
 
 
 
Fig. 10: pBluescript II  KS (+) 
The plasmid was used for aptamer 
sequencing and contains the f1 (+) 
origin of ss-DNA replication, β-
galactosidase α-fragment coding 
sequence (lacZ’), pUC origin of 
replication and ampicillin resistance 
(bla) ORF. 
 
 
 
Fig. 11: Plasmid pRVHBV1.0 + 
The plasmid contains the whole HBV 
genome. 
precore 
preS2 
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Fig. 12: pSVHBV1.1LE- 
The plasmid was derived from 
plasmid pSVHBV1.5LE- and carries 
the entire HBV genome with 2 stop 
codons in the preS2 and S domains, 
respectively which leads to a non-
functional envelope protein ORF 
(polymerase ORF not affected). 
After transfection of cells with this 
plasmid, only capsids and no virions 
are produced. 
 
 
 
Fig. 13: pSVHBV1.1LE-I126A 
The plasmid is the same like the 
plasmid pSVHBV1.1LE- except for 2 
point mutations (A5608G and T5609C) 
changing codon 126 of the core gene 
and amino acid 126 of the core protein 
from isoleucine to alanine. Capsids with 
this point mutation can not be 
enveloped. 
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4.1.15 Solutions and Buffer systems 
100x BSA New England Biolabs 
10x DNA-loading buffer 50 % Glycerin, 0.5% Bromphenolblau, 0.5% 
Xylencyanol  
5x Loading buffer for SDS-PAGE 250 mM Tris HCl pH6,8, 10 % SDS, 7.5% Glycerin, 
0.5 % Bromphenolblue, 1,6 M DTT 
10x NEB-buffer 3 New England Biolabs 
10x PBS 180 mM NaCl, 8.5 mM Na2HPO4, 2.2 mM KH2PO4 
2x Proteinase K buffer 2% (w/v) SDS, 20 mM Tris-HCl, 20 mM EDTA pH 
7.5 
6x Protein loading buffer for 50 % Glycerine (v/v), 0.05 % Bromphenolblue (w/v), 
 
 
Fig. 14: pSV45-57 
The plasmid codes for all three HBV 
surface proteins under control of a 
SV40 promoter but it lacks the first 30 
codons for the large envelope protein. 
The shortened L sequence allows 
more efficient secretion of viral 
particles. This plasmid carries an 
ampicillin resistance gene.  
  
 
 
 
Fig. 15: pSVBX24H 
The plasmid contains the ORF for the 
HBV small surface protein under 
control of the SV40 promoter. The 
vector backbone also carries an 
ampicillin resistance for selection in 
bacteria. It is used in combination 
with plasmid pSV45-57 and plasmid 
pSVHBV1.1LE- for production of 
virions upon transfection in HUH7 
cells. 
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native gels 0.05 % Xylenecyanol FF (w/v), 6x TAE-Puffer 
10x SDS-running buffer 0.25M Tris, 1.92 M Glycine, 1% SDS 
20x SSC-buffer 3 M NaCl, 0.3 sodium Citrate Dihydrate 
50x TAE 2 M Tris HCl pH 6.8, 50 mM EDTA 
1000x Trace elements 50 mM FeCl3, 20 mM CaCl2, 10 mM MnCl2, 10 mM 
ZnSO4, 2 mM CoCl2, 2 mM CuCl2, 2 mM NiCl2, 2 
mM Na2MoO4, 2 mM Na2SeO3, 2 mM H3BO3 
10 x Transfer buffer salts 28.4 g Tris, 144g Glycine into 1l H2O 
Blocking buffer 10% skim milk powder (w/v), 0.1% Tween 20 in 1x 
PBS 
Cathode transfer buffer Transfer buffer, 0.5% (w/v) SDS  
Coomassie Brilliant Blue staining 
solution 
0.25 g Coomassie Brilliant Blue (R-250), 90 ml 
methanol : H2O (1:1); 10 ml glacial acetic acid 
Coomassie Brilliant Blue 
destaining solution 
90 ml methanol : H2O (1:1), 10 ml glacial acetic acid 
Diffusion buffer 0.5 M Amm.acetate, 10 mM Mg acetate, 1  mM 
EDTA, 0.1 % SDS              
Gel drying solution 4% glycerol, 20% ethanol in H2O 
Li- Cl Fluka 
Lysis buffer  5 mM EDTA, 50 mM Tris HCl pH 8.0, 2 mg/ml 
Lysozyme 
NaOH/SDS 440 μl  10M NaOH, 1.2 ml 20% SDS, 20.46 ml H2O 
Poncceau S Sigma 
Solution I (Plasmid preparation) 50 mM Glucose, 25 mM Tris HCl pH8, 10 mM EDTA 
Solution II (Plasmid preparation) 0.2 NaOH, 1 % (w/v) SDS  
Solution III (Plasmid preparation) 3 M Potassium, 5 M acetate pH 5.5 
Solution IV (Plasmid preparation) 13 % (w/v) PEG 6000,1.6 M NaCl 
Streptavidin buffer 10 mM Tris-HCl, 50 mM  NaCl,  1  mM EDTA      
T4 DNA Ligase buffer Fermentas 
TBS 50 mM Tris HCl pH 7.4, 150 mM NaCl 
TE-buffer 10 mM Tris HCl pH 8.0, 1mM EDTA 
TNE-buffer 10 mM Tris HCl pH 7.5, 10 mM NaCl, 20 mM EDTA 
Trans-Blot Transfer-Medium  Biorad 
Transfer buffer 20 % Methanol, 1x Transfer buffer salts 
Washing buffer (PBS-T)  0.1% Tween 20 in PBS 
4.1.16 Primers 
VBAO01 5´ GCGGCCATGGACATTGACC ´3 
VBAO02 5´ GCGGGTCGACTTATTAAACAACAGTAGTTTCC ´3 
VBAO03 5´ CCGCCCATGGATGTG ´3 
VBAO04 5´ GCGGGTCGACGTTTG ´3 
VBAO05 5´ GGCGAGAAAGGAAGGGAAGAA ´3 
VBBS8      5´ GCTGAGGCGGTGTCTAGGAGA ´3 
VBBS18    5´ GGCATAAATTGGTCTGCGCACC ´3 
Mater ia l  and  me thods  
 
 
[34] 
4.1.17 Software 
Ammoniumsulfate calculator www.encorbio.com/protocols/AM-SO4.htm              
ClustalW2 http://www.ebi.ac.uk/Tools/clustalw2/index.html         
Mfold (version 3.2) http://mfold.bioinfo.rpi.edu/ cgi-bin/dna-form1.cgi 
Microplate Manager 4.0 Biorad 
Microsoft Excel 2007 Microsoft 
Oligo Calc http://www.basic.northwestern.edu/biotools/oligocalc.html 
Quantity One 4.1.1. Biorad 
Reverse Complement http://www.bioinformatics.org/sms/rev_comp.html    
SigmaPlot12.0 Sigma 
Simple Reads Online GE Healthcare 
Unicorn 5.20  GE Healthcare 
Vector NTI Advance 10 Invitrogen 
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4.2 Methods 
4.2.1 DNA Technology 
4.2.1.1 Conventional polymerase chain reaction (PCR) 
The technique was developed in 1983 by Kary Mullis (Bartlett and Stirling, 2003). Taq 
polymerase was used in this work. All PCR reactions were carried out in a volume of 50 μl. 
Primers were used in a concentration of 1 μM. The annealing temperature was calculated by 
taking the mean value of the melting temperature of the primers and subtracting 5
o
C. 
Extension time was approximately 1 minute per 1000 bp. 
4.2.1.1.1 PCR during HBV WT and mutant capsid expression 
The sequences in the plasmids pRVHBV+ and pSVHBV 1.1LE- which encode for WT and 
I126A-mutant HBV capsids, respectively were amplified by PCR using specific primer set 
VBAO01 and VBAO02. This primer set allows the amplification of the sequences which 
encode for HBV capsids but with deleted 36 aa at the C-terminal end (Table 1 and 2). 
Table 1: PCR reagents used during WT and mutant HBV capsids gene amplification:  
Reagents Amounts 
pRVHBV
+
/ pSVHBV 1.1LE- 10 pg   
Primer VBAO 01 (50 pmol/µl)   1 µl 
Primer VBAO 02 (50 pmol/µl)   1 µl 
2x Roche Mastermix  25 µl (0.05 U Taq/μl) 
H2O variable 
Total volume 50 µl 
Table 2: PCR thermal profile used during WT and mutant HBV capsids expression: 
PCR steps Test  Number of cylcles 
Denaturation 94 °C   5 min 1 
Denaturation 94 °C 30 sec  
30 Anealing  54 °C 30 sec 
Elongation 72 °C   1 min 
Elongation 72 °C   7 min 1 
Cooling    4 °C  
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4.2.1.1.2 PCR during aptamer selection and sequencing 
For the improvement of the random DNA library amplification and to reduce the formed single 
strand-double strand hybrids and the PCR by-products, higher concentration of Taq polymerase 
(0.1 U / reaction) was used as well as fewer PCR cycles (15 cycles) were performed (Table 3 
and 4).  
During the aptamer selection, reverse biotinylated primer (VBAO03) and forward non- 
biotinylated one (VBAO04) were used while for the molecular cloning of the selected 
aptamers for sequencing the same both primers were used but in a phosphorylated form. 
Table 3: PCR reagents used during aptamer selection and sequencing: 
Reagents Amounts 
Aptamers 10 ng  
Primer VBAO 03 (50 pmol/µl)   1 µl 
Primer VBAO 04 (50 pmol/µl)   1 µl 
2x Promega Mastermix (0.05 U/μl) 25 µl  
AmpliTaq Gold DNA Polymerase   1 µl (5 U) 
H2O variable 
Total volume 50 µl 
Table 4: PCR thermal profile used during aptamer selection: 
PCR steps Test  Number of cylcles 
Denaturation 95 °C   5 min 1 
Denaturation 95 °C 20 sec  
15 Anealing  51 °C 15 sec 
Elongation 72 °C 10 sec 
Elongation 72 °C   2 min 1 
Cooling    4 °C  
4.2.1.2 Purification and concentration of DNA 
4.2.1.2.1 Phenol-chloroform extraction 
DNA can be purified efficiently from proteinaceous and fatty impurities by using phenol/ 
chloroform/ isoamyl alcohol mixture. The samples were mixed well with equal volumes of 
phenol/ chloroform/ isoamyl alcohol, then by centrifugation a biphasic mixture was formed 
where the fats collected in the lower organic phase and the DNA solved in the upper phase 
while the denatured proteins aggregated in the interphase. The upper phase containing the 
aimed DNA was transferred to another new tube. Then the same procedure was repeated three 
times, and finally the DNA was precipitated by ethanol. 
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4.2.1.2.2 Ethanol precipitation of DNA 
The extracted, restricted or ligated DNA molecules in aqueous solutions were purified and/or 
concentrated by ethanol precipitation. The sample was mixed with 1/10 volume of 3 M 
sodium acetate pH 5.6 and two volumes of 96% ethanol and be frozen at -80
o
C for one hour, 
then centrifuged at 13000 rpm for half an hour. The supernatant was discarded and the pellet 
washed once with 70% ethanol and air dried and finally resuspended with an adequate volume 
of DNase free water. 
4.2.1.2.3 Purification of DNA solutions and PCR products 
The QIAEX II Gel Extraction kit (Qiagen) was used to purify and concentrate DNA solutions 
and PCR products. According to the manufacturer instructions, three volumes (for DNA from 
100 bp – 4 kb) or six volumes (for DNA ≤ 100 bp) of buffer QX1 were added to the sample. 
10 μl from the pre-vortexed QIAEX II was added and the mixture incubated at room 
temperature for 10 min with intermittent vortexing every 2 min to keep QIAEX II in a 
suspension form. The mixture was centrifuged and then the pellet was washed twice using 
buffer PE. The pellet was air dried for 10 min and finally, the DNA was eluted by 
resuspending the pellet in 20 μl Tris.Cl, pH 8.5 and incubating it at room temperature for 5 
min. beforecentrifugation. The elution step was repeated to improve the DNA recovery. 
4.2.1.3 Gel electrophoresis 
4.2.1.3.1 Agarose gel electrophoresis 
In this work, 1% agarose gels were prepared for large DNA fragments. The gels were prepared 
with 1×TAE buffer and 0.5 μg/ml ethidium bromide (EtBr). The gels were run in 1×TAE buffer 
with a voltage of 8 V/cm. The gels were visualized under ultraviolet (UV) light. 
4.2.1.3.2 Denaturing urea–polyacrylamide gel electrophoresis (PAGE) 
Polyacrylamide gel electrophoresis (PAGE) was used to separate and purify ssDNA where the 
denatured DNA migrates through these gels at a rate that is almost completely independent of 
its base composition and sequence because these gels polymerized in the presence of urea to 
suppress base pairing in nucleic acids. In this work, gels containing 6 M urea and 10% 
acrylamide were prepared (Table 5). The gels were run at 15 V/cm in 1×TBE buffer. The gels 
were stained by soaking in EtBr solution (1 μg/ml) for 30 min and visualized on an ultraviolet 
transilluminator. 
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Table 5: Contents of denaturing urea–polyacrylamide gel: 
Acrylamid concentration  10 %  
30% Acrylamid/bisacrylamide (29:1)  36 ml  
10×TBE buffer  10 ml  
Urea  36 g  
H2O  Up to100 ml  
APS (10%)  0.5 ml  
TEMED  200 μl 
4.2.1.4 Extraction of DNA from gels 
4.2.1.4.1 Extraction from agarose gel 
The QIAquick Gel Extraction Kit (Qiagen) was used to isolate and extract DNA from gels. 
Following the manufacturer instructions, three volumes of QG buffer were added to the 
weighted excised gel piece (300 μl QG buffer /100 mg gel) and incubated at 50oC for 10 
minutes with intermittent vortexing every 2-3 minutes till the gel was completely dissolved. 
Then one gel volume isopropanol was added with proper mixing. The mixture was applied 
onto a QIAquick column and centrifuged for one minute to allow the DNA binding to the 
column matrix. This was repeated twice. Then, for removing all gel traces, three steps of 
washing was done, one with 500 μl of buffer QG followed by two times with 0.75 ml of 
buffer PE. An additional centrifugation step was done to dry the column. Finally, the DNA 
was eluted by applying 30 μl water to the column before centrifugation. The elution step was 
repeated using the flow through of the first one to enhance DNA recovery. 
4.2.1.4.2 Extraction from polyacrylamide gel 
The QIAEX II Gel Extraction Kit (Qiagen) was used to isolate and purify aptamers from 
denaturing urea–polyacrylamide gel. Firstly, the excised gel was weighted and crushed into 
very small pieces using a sterile pestle, then two volumes of the diffusion buffer were added 
(200 μl diffusion buffer /100 mg gel). The mixture was incubated overnight at 37oC in the 
thermomixer with shaking at 350 rpm. A centrifugation step at 10,000 rpm for 5 min at 4
o
C 
was done and the supernatant was carefully aspirated and passed through packed, silanized 
glass wool to remove any residual polyacrylamide. The volume of the recovered supernatant 
was calculated, then the same steps of purification of DNA solutions and PCR products were 
done (see 4.2.1.2.3). 
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4.2.1.5 Streptavidin induced electrophoretic mobility shift for ssDNA 
preparation 
Streptavidin induced electrophoretic mobility shift is an efficient and rapid method that allows 
the purification of ssDNA of uniform size from PCR products. This method exploits the 
remarkable stability of the biotin–streptavidin interaction under strongly denaturing 
conditions. The DNA was PCR amplified using a biotinylated primer, complementary to the 
target single stranded DNA (the forward strand), together with an unmodified primer. The 
PCR product was purified using the QIAEX II Gel Extraction kit to remove unincorporated 
primers and also to reduce the volume, and then the recovery was resuspended with an 
adequate amount of streptavidin buffer to be incubated with streptavidin at room temperature 
for 30 min (1:4 molar ratio of biotinylated primer to streptavidin). The binding mix is then 
denatured and electrophoresed on a 10% polyacrylamide, 6 M urea gel (Fig. 16). The free 
ssDNA (non-biotinylated lighter, lower band) is then purified by passive elution from the 
crushed acrylamide gel together with the QIAEX II kit as in 4.2.1.4.2.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 16: Streptavidin induced electrophoretic mobility shift for ssDNA preparation 
4.2.1.6 Determination of DNA concentrations 
The absorbance at wavelength 260 nm (A260) can be used for determination of nucleic acid 
concentrations in solutions. The concentration to absorbance relation can be defined by the 
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Lambert–Beer Law, OD = e * c * d. The optical density (OD) is the product of the substance 
specific extinction coefficient (e), the concentration of the absorbing sample (c), and the optical 
path length in cm (d). The absorbance to concentration conversion are 1 OD260= 50 μg/ml for 
dsDNA, 1 OD260= 33 μg/ml for ssDNA and 1 OD260= 40 μg/ml for RNA. The absorbance at 
wavelength 280 nm (A 280) was used to measure protein concentration. A ratio of A260/A280=2 
supposed to be the value for pure DNA. 
In this work, a nanodrop machine was used for determining DNA concentrations where 2 μl of 
the undiluted sample were measured two times. A photometer was also used for determining 
DNA concentration where three measurements were made for 100-fold diluted sample. 
4.2.1.7 DNA Cloning 
4.2.1.7.1 DNA restriction 
DNA can be cut into desired fragments using specific restriction enzymes. These specific 
restriction enzymes are chosen to cut the DNA at a specific palindromic site. Depending on 
the enzyme used, the cut DNA either has blunt or overhanging ends (sticky ends). 
4.2.1.7.1.1 Single digestion and dephosphorylation of the plasmid DNA 
For molecular cloning of a DNA molecule the vector is cut using restriction enzymes. The 
vector is after dephospohrylated by using alkaline phosphatase to prevent vector self-ligation. 
Finally, the target DNA molecule was amplified by PCR using 5′ phosphorylated primers so 
that the product can be ligated to the dephosphorylated, linearized vector.  
During the aptamer cloning, the vector was singly cut by the restriction enzyme EcoRV and 
dephosphorylated simultaneously by using Calf Intestinal Phosphatase (CIP). The mixture 
(Table 6) was incubated at 37
o
C overnight and finally the restricted dephosphorylated vector 
was purified using the QIAEX II kit as described in 4.2.1.2.3 to be ready for the ligation step.  
Table 6: DNA restriction scheme during aptamer cloning: 
Reagents   Amounts 
Vector    4 μg 
EcoRV (10 U/μl)   5 μl 
CIP   1 μl 
10x NEB-Buffer 3   5 μl 
10x BSA   5 μl 
H2O 30 μl 
Total volume 50 μl 
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4.2.1.7.1.2 Double digestion of DNA 
Another approach for molecular cloning of a DNA molecule is to doubly cut the vector using 
two restriction enzymes which cut the DNA leaving sticky ends (overhangs) that are 
complementary to the other sticky ends of the restricted DNA molecule for insertion. 
During the construction of expression vector for WT and mutant HBV capsids, the vector and 
the DNA sequences that encode for the capsids were doubly cut by the restriction enzymes 
NcoI and SalI. The mixture (Table 7) was incubated at 37
o
C for 2 hours and then the restricted 
DNA was purified by the QIAquick Gel Extraction kit as described in 4.2.1.4.1 to be ready 
for the ligation step. 
Table 7: DNA restriction scheme during WT and mutant HBV capsids preparation:  
Reagents  Vector Insert   
DNA    0.1 μg    3 μg 
SalI (20 U/μl)   0.5 μl   1 μl 
NcoI (10 U/μl)   1.0 μl   2 μl 
10x NEB-Buffer 3   2.0 μl   5 μl 
10x BSA   2.0 μl   5 μl 
H2O variable variable 
Total volume 20 μl 50 μl 
4.2.1.7.2 DNA Ligation 
The in vitro ligation between the DNA molecule to be inserted into the vector and the vector 
was carried out by T4 DNA ligase which builds phosphodiester bonds between 3’and 5′ 
ends. The mixture (Table 8) was incubated at 16 
o
C overnight and then the ligated DNA was 
purified by ethanol precipitation as described in 4.2.1.2.2 prior to the bacterial 
transformation.  
Table 8: DNA insert/vector ligation scheme during WT and mutant HBV capsids 
preparation:  
Reagents  Amounts   
Vector   3 μl 
Insert   8 μl 
T4 DNA Ligase   1 μl 
10x T4 DNA Ligase Buffer   2 μl 
H2O   7 μl 
Total volume 20 μl 
  
Mater ia l  and  me thods  
 
 
[42] 
4.2.1.7.3 Transformation of bacteria with ligated DNA 
The introduction of exogenous DNA molecules into bacterial cells requires an artificial 
competence of these cells to make them passively permeable to DNA. This can be done by 
exposing them to conditions that do not normally occur in nature. In this work, two types of 
competent cells were used, electrocompetent and thermocompetent cells. 
4.2.1.7.3.1 Preparation of electrocompetent bacteria 
The electrocompetent E. coli DH10B bacterial cells were produced by inoculating 1.5 ml of a  
dense DH10B culture into 250 ml of LB medium free from any antibiotics and by incubation 
at 37
o
C overnight. Once the OD of the culture reached 0.6-1 at 578 nm, the cells were 
harvested as this means that the bacterial growth reached the logarithmic phase. The harvested 
bacteria were then kept on ice for 20 min and subsequently centrifuged at 5000 rpm for 15 
min at 4
o
C to be washed twice with 250 ml of ice-cold water and finally once with 10 ml of 
ice-cold, sterile 10% glycerol. The centrifugation during the washing steps was done at 5000 
rpm for 12 min at 4
o
C. Finally the cell pellets were resuspended in 1.5 ml of ice-cold and 
sterile 10% glycerol and divided into aliquots of 55 μl and then stored at -80oC. 
4.2.1.7.3.2 Transformation of electrocompetent cells 
The frozen electrocompetent E. coli DH10B cells were thawed on ice and only 25 μl of 
thawed cells were mixed with 1 μl prediluted DNA (1/10000 – 1/100000 dilution of large 
scale plasmid preparation or 1/5 dilution of DNA samples from ligation). The mixture was 
loaded into a ice precooled 0.1 cm pulser cuvette (Biorad) and electroporated at 1.8 kV then 
immediately 1 ml of 37
o
C prewarmed LB was added on them. The mixture was transferred 
into a 1 ml Eppendorf tube and shaken in a thermomixer at 450 rpm and 37
o
C for 30 min. The 
cells were collected by centrifugation at 3000 rpm for 5 min, the supernatant was removed 
and then the cells were resupended into 50 μl LB to be streaked out on agar plates containing 
the proper antibiotic (Canamycin 30 mg/ml or Ampicillin 100 μg/ml). Finally, the plates were 
incubated overnight at 37
o
C. 
4.2.1.7.3.3 Transformation of thermocompetent cells 
The frozen thermocompetent E. coli BL21 Star (DE3) pRARE2 cells were thawed on ice and 
only 100 μl of thawed cells were mixed with 1 μl prediluted DNA. Then the mixture was 
incubated on ice for 30 min. The cells were heat shocked by heating them at 42
o
C for 45 
seconds. The heat shocked cells were kept on ice for 2 minutes to allow the closure of the 
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cellular pores. Finally, 4-volumes of prewarmed LB were added and the mixture incubated at 
37
o
C for 1 hour. The cells streaked out on agar plates containing Canamycin 30 mg /ml and 
then the plates were incubated overnight at 37
o
C. 
4.2.1.7.4 Plasmid preparation 
4.2.1.7.4.1 Low scale preparation (Miniprep) 
A single colony containing the desired plasmid from transformed E. coli bacteria was 
subcultured in 4 ml of LB containing the appropriate antibiotic (Canamycin 30 mg/ml or 
Ampicillin 100 μg/ml) and incubated overnight at 37oC with shaking at 260 rpm. Then 3 ml 
were pelleted by centrifugation at 9000 rpm for 3 min. The cells were taken up in 100 μl of 
solution I, lysed by adding 200 μl of freshly prepared solution II with gentle shaking and 
incubation at room temperature for 5 min.  After that 150 μl of solution III were added to the 
mixture and cooled on ice for 5 min to allow the neutralization of the pH. The mixture was 
centrifuged at 13000 rpm for 10 min at 4
o
C and then the supernatant was transferred to new 
eppendorf tube to be centrifuged once more to assure the removal of all cellular debris and 
proteinaceous wastes. Finally, the plasmid DNA was concentrated by ethanol precipitation 
and the pellet was resuspended into 30 μl of water containing 0.5 μl of RNase A. The 
prepared plasmid was stored at -20
o
C.       
4.2.1.7.4.2 Medium scale preparation (Midiprep) 
This was done by using the Qiagen Plasmid Midi kit. A single colony containing the desired 
plasmid was inoculated into 100 ml of LB medium with 100 μg/ml ampicillin and incubated 
overnight at 37
o
C with shaking at 260 rpm. The DNA was isolated and purified according to 
the manufacturer’s protocol. At the end the DNA pellet was dissolved in 100 μl of water. 
4.2.1.7.4.3 Large scale preparation (Maxiprep) 
A single colony containing the desired plasmid was subcultured in 30 ml of TB medium 
containing the appropriate antibiotic (canamycin 30 mg/ml or ampicillin 100 μg/ml) and 
incubated overnight at 37 
o
C with shaking at 260 rpm. The cells were collected by 
centrifugation at 4000 rpm for 15 min at 4
o
C. The sedimented cells were resuspended in 5 ml 
of cold solution I. Then 10 ml of freshly prepared solution II was added with gentle mixing 
and the mixture left at room temperature for a period not exceeding 5 min to allow cell lysis 
without DNA damage by the high pH of solution II. The high pH was neutralized by adding 
7.5 ml of solution III with cooling the mixture on ice for 5 min. Then 2 centrifugation steps 
Mater ia l  and  me thods  
 
 
[44] 
were performed at 4000 rpm for 10 min at 4
o
C to remove all the cellular debris from the 
supernatant which contains the plasmid DNA. The DNA was precipitated by adding 0.6 
volumes (13.5 ml) of isopropanol on the supernatant, mixing and incubation for 3 minutes at 
room temperature. After that the solution was centrifuged at 4000 rpm for 10 min at 4
o
C. The 
pellet was dried on air and resuspended in 3 ml of TE buffer. 3 ml of -20
o
C precooled 5 M 
LiCl were mixed with the resuspended pellet and centrifuged at 4000 rpm for 15 min to 
precipitate the RNA. The DNA in the supernatant was precipitated with an equal volume of 
isopropanol at 4000 rpm for 15 min. After air drying of the pellet, it was dissolved in 500 μl 
of TE buffer containing 1 μl of RNase and left at room temperature for half an hour to assure 
the complete digestion of RNA in the sample. Then 500 μl of solution IV was mixed with the 
mixture and a centrifugation step at 13000 rpm for 15 min was done. The pellet was air dried, 
then dissolved in 400 μl of TE buffer. The solution was extracted by phenol choloroform and 
ethanol precipitated (see above). Finally, the desired plasmid DNA pellet was dissolved in 
100-300 μl of water and preserved at -20oC.   
4.2.1.8 DNA sequencing 
DNA sequencing was performed by the company GATC Biotech. The results were analyzed 
by the help of computer programs, Vector NTI (Invitrogen) for identifying the plasmids’ 
genetic maps, ClustalW2 of the European Molecular Biology laboratory – European 
Bioinformatics Institute (EMBL-EBI; http://www.ebi.ac.uk/Tools/clustalw2/index.html) for 
aligning the sequenced DNA and Reverse Complement (http://www.bioinformatics.org/sm 
s/rev_comp.html) for converting the sequences to the complementary sequence. 
4.2.1.9 DNA quantification by specific Real-Time PCR 
HBV viral genomes isolated from virions or the selected aptamer were quantified by 
quantitative PCR (qPCR). The dye used was SYBR Green which binds unspecifically to 
double stranded but not the single stranded DNA. 
4.2.1.9.1 qPCR standards 
For the quantification of HBV viral genomes isolated from virions, five 10-fold serial 
dilutions (10
2
-10
6
) of plasmid pSVHBV1.5LE- were used as standard because the qPCR 
primer set (VBBS8 and VBBS18) produces the same 222 bp DNA fragment as the HBV 
genome. These plasmid dilutions were made after adjusting the plasmid concentration using 
spectrophotometer and according to the plasmid molecular weight which was calculated using 
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a oligonucleotide properties calculator (http://www.basic.northwestern.edu/biotools/            
oligocalc.html).  During the aptamer selection process, six 10-fold serial dilutions (10
2
-10
7
) of 
the ordered random DNA aptamer library (PURIMEX) was used as a standard while during 
the evaluation of the selected aptamers, six 10-fold serial dilution (10
2
-10
7
) of one ordered 
selected aptamer (AO-01) was used.  
4.2.1.9.2 qPCR setup and program 
All qPCR reactions were carried out in a volume of 20 μl. Primers were used in a 
concentration of 1 μM. The reactions were carried out in 96-well plates which were sealed 
with adhesive foil (Roche). The qPCR reagents were used in concentrations according to the 
manufacturer instructions (Table 9). To run and analyze the qPCR, the Roche LightCycler 
480 II and its software release 1.5.0 SP4 (version 1.5.0.39) were used.  In this work, the 
“SYBR Green I 96-II” program was used with minor modifications (Table 10).  
Table 9: qPCR reagents used during the quantification of HBV genomes or selected 
aptamer: 
Reagents Amounts  
DNA diluted in Roche PCR grade water  9.6 µl  
Primer VBBS8     (100 pmol/µl) or 
Primer VBAO 03 (100 pmol/µl) 
0.2 µl 
Primer VBBS18   (100 pmol/µl) or 
Primer VBAO 04 (100 pmol/µl) 
0.2 µl 
Roche SYBR Green I Master  10 µl  
Total volume 20 µl 
Table 10: qPCR thermal profile used during the quantification of HBV genomes or 
selected aptamer: 
 
PCR steps HBV genome Aptamers Cylcles 
Denaturation 95 °C  5 min 95 °C  5 min 1 
Denaturation 95 °C 20 sec 95 °C 20 sec  
30 Anealing  60 °C 10 sec 51 °C 15 sec 
Elongation 72 °C 10 sec 72 °C 10 sec 
Melting curve of PCR products  
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4.2.2 Protein Technology 
4.2.2.1 Protein expression 
The HBV wild type and mutant (I126A) capsids were over-expressed into E. coli BL21 Star 
(DE3) pRARE2 cells. Firstly, a single colony from the transformed cells was subcultured into 
5 ml LB-Medium containing antibiotics (Canamycin 30 mg/ml, Chloramphenicol 33 mg/ml) 
and incubated overnight at 37
o
C with shaking at 220 rpm. In the next day, the cultured cells 
were transferred to 500 ml 2XYT medium  with antibiotics (Canamycin 30 mg/ml, 
Chloramphenicol 33 mg/ml) and incubated at 37 °C with shaking at 220 rpm with intermittent 
checking (every 1-2 hours) of the OD using a spectrophotometer. When the bacterial culture 
OD reached 0.7-1 it was cooled down to 20 °C, then 200 μM isopropyl-β-D-
thiogalactopyranoside (IPTG) were added to induce the protein expression and finally the cell 
culture was incubated overnight at 20 °C with shaking at 220 rpm.  
Finally, the cultured cells were centrifuged at 6000 rpm for 20 minutes at 4°C (Thermo 
Scientific Rotor SCL 6000). The sedimented cells were dissolved in an adequete amount of 
medium and centrifuged again but at 14000 rpm for 15 min at 4°C. Then the precipitated cells 
were preserved at -80°C.  
4.2.2.2 Protein Purification 
4.2.2.2.1 Cell lysis 
The bacterial pellet was dissolved in 20 ml of lysis buffer then it was incubated on ice for 
30 min and subjected to 4 steps of repeated freezing (at -80°C) and thawing (at 37°C in a 
water bath). The lysed cells were left on ice and 1 ml of DNase/MgCl2 solution (200 µg 
DNase in 0.1 M MgCl2) was added and the mixture was incubated at room temperature for 
15 min to allow the destruction of cellular DNA. Finally, the cell lysate was centrifuged at 
15000 rpm for 10 min at 4 
o
C (Thermo Scientific Rotor SS34) and the supernatant which 
contained the capsids was preserved at -20
o
C.  
4.2.2.2.2 Protein precipitation 
Proteins can be extracted from a solution by ammonium sulphate as ammonium sulphate 
can change the interaction between the ionizing groups of amino acids and the H2O 
molecules leading to aggregation of proteins which then can be separated easily by 
centrifugation.  
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In this work, 50% ammonium sulphate was used for precipitating the HBV capsids. The 
amount of the ammonium sulphate was determined by using a software, Ammonium 
Sulphate Calculator, (www.encorbio.com/protocols/AM-SO4.htm). The calculated amount 
of ammonium sulphate was added gradually to the protein solution with gentle mixing using 
a magnetic stirrer in a cold room at 4
o
C and the mixture left for additional 30 min at 4
o
C 
with continuous shaking. Finally, the protein was precipitated by centrifugation at 19000 
rpm for 30 min at 4
o
C (Rotor SS34) and then the pellet was resuspended in 10 ml of 
TBS/0.1 %NP-40. 
4.2.2.2.3 Protein concentration 
The protein was concentrated by using a concentrator (Millipore 30000) with a cut off of 30 
KDa. The protein solution was loaded into the concentrator and then centrifuged at 4000 
rpm for 20 min at 4 °C. Finally, the concentrated protein was preserved at -80
o
C.  
4.2.2.2.4 Chromatography 
4.2.2.2.4.1 Sephacryl S-500 HR column 
For the purification of large molecules, Hiprep 26/60 Sephacryl S-500 HR (GE Healthcare) 
columns can be used (size exclusion chromatography). The used column was connected to 
the Akta Purifier apparatus (GE Healthcare), and the purification conditions were adjusted 
and controlled using the software Unicorn 5.20 (GE Healthcare). 
The sample was loaded into the TBS-preequilibrated column and then it was pumped 
automatically by the pump (P-900) in a rate of 2.6 ml/min. Throughout the sample 
partitioning, the absorption of the elutes were measured at wavelengths 254 and 280 nm 
(UV-900). Furthermore, the conductivity of the sample was measured (C-900). Finally, the 
elutes were collected in fractions, each of 5 ml. The elutes showing high absorbance at 
wavelength 280 nm were pooled. The final volume was 100 ml. The sample was preserved 
at 4
o
C.  
4.2.2.2.4.2 PD-10 desalting column 
The purification, desalting or even changing the buffer of a sample can be done by using 
PD-10 columns (GE Healthcare). The cut off of this column is 5 KDa. The procedure was 
done according to the manufacturer protocol (Gravity protocol). 
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4.2.2.2.5 Sucrose gradient ultracentrifugation 
One method for virus purification is sucrose gradient ultracentrifugation. In this work, six 
different sucrose fractions were prepared (10 %, 20 %, 30 %, 40 %, 50 %, 60 % (w/v)) with 
TBS buffer pH 7.4 and then 6 ml from each fraction were loaded slowly into ultraclean 
centrifugation tube (Beckman) starting with the highest concentration. The sample (2.5 ml) 
was loaded on the top of the gradient. The centrifugation was done in a SW28 rotor at 10 °C 
and 25000 rpm for 24 h. Finally, the fractions were collected carefully from the top; each 
fraction was 1 ml in volume. They were preserved at 4
o
C. 
4.2.2.3 Protein detection 
4.2.2.3.1 SDS-PAGE 
Sodium Dodecyl sulfate polyacrylamide gel electrophoresis (SDS–PAGE) is a technique to 
separate proteins according to their electrophoretic mobility. SDS, an ionic detergent, which 
denatures secondary and non–disulfide–linked tertiary structures, applies a negative charge to 
each protein in proportion to its mass. So SDS–protein complexes can migrate through the gel 
in accordance to the size of the protein. 
In this work, a gel composed of 15% separating gel and 5% stacking gel was used (Table 11). 
The samples were mixed with 5x SDS-loading buffer with DTT (0.125 g DTT/500 µl) and 
heated at 95 °C for 5 min before being loaded into the gel to allow the protein disintegration 
into its monomer structure. Furthermore, the SDS ensures that the proteins is uniformly charged 
negatively and thus can be separated by means of gel electrophoresis. The predenatured protein 
samples and 10 μl of the protein marker „Page Ruler or Page Ruler Plus prestained Protein 
Ladder“ (Fermentas) were loaded into the prepared gel and then run in 1x SDS running buffer 
at 200 V for 2 h. Then it was stained by coomassie brilliant blue staining solution or run at 30 V 
overnight when it was electro-blotted to be detected by the HBV anti-core antibody. 
Table 11: Reagents for15 % separating and 5 % stacking SDS gels 
Reagents Separating 15 % Stacking 5 % 
1.5 M Tris HCl buffer pH 8.8 2.5 ml - 
1.0 M Tris HCl buffer pH 6.8 - 0.63 ml 
10 % SDS buffer 0.1 ml 0.05 ml 
30 % Acrylamide Mix 5 ml 0.83 ml 
10 % Ammonium persulphate 0.1 ml 0.05 ml 
TEMED 0.004 ml 0.005 ml 
H2O 2.3 ml 3.4 ml 
Total volume 10 ml 5 ml 
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4.2.2.3.2 Agarose gel electrophoresis 
The separation of the native HBV capsids was done by electrophoresis in 1 % agarose gels. 
The samples were diluted in TNE-buffer pH 7.5 and mixed with 6x native protein loading 
buffer without any reducing agent to keep the capsids intact without any disintegration. The 
samples, the positive control and the marker were loaded into the gel and run at 65 V for 2 h. 
Finally, the loaded samples were capillary blotted (see 4.2.2.3.3) and detected using an HBV 
anti-core antibody (see 4.2.2.3.5). 
4.2.2.3.3 Capillary blotting 
The protein samples on agarose gels were transferred to nitrocellulose membranes by 
capillary blotting which depends on the diffusion of the protein particles within the buffer 
flow from the gel to the nitrocellulose membranes which have high protein-binding affinity. 
In this work, a long 3 mm Whatman blotting paper (Schleicher und Schüller) was cut to the 
gel width and immersed in 10X SSC buffer and then left on a glass plate while its both ends 
still immersed in the buffer to allow the continuous buffer flow through the paper. In the 
middle of this paper, 5 small 10X SSC prewetted Whatman blotting papers were located and 
over them the gel was laid but in an inverted position. A nitrocellulose membrane (0.45 µm) 
was wetted with water, laid over the gel and on it the lanes were marked using a pen. Over the 
membrane additional 5 small 10X SSC prewetted Whatman blotting papers were placed and 
the air bubbles among the different layers were removed by rolling them out with a pipette. 
To avoid the loss of the buffer on the sides, long pieces of parafilm were placed on the glass 
plate and around the layers. Finally, a stack of dry papers was put on the top. To facilitate the 
buffer flow through the layers a 1 kg weight was put on the top and then the whole layers 
were left overnight at room temperature. In the next day, the blotted membrane was carefully 
removed and incubated in the blocking buffer overnight at 4
o
C. 
4.2.2.3.4 Electro blotting 
The electroblotting is a simple and fast method used to transfer proteins from polyacrylamide 
gel to a nitrocellulose membrane depending on the electrophoretic properties of the protein.   
In this work, the semi dry electroblotting was done using the Fastblot Semi-Dry 
Electrophoretic Transfer Apparatus from Biometra. Firstly, the SDS-gel containing samples 
and the nitrocellulose membrane (0.45 µm) were immersed in an adequate amount of transfer 
buffer and left at room temperature for 10 min. 5 transfer buffer prewetted Whatman blotting 
papers were put onto the anode of the electroblot machine and over them the nitrocellulose 
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membrane then the gel and finally additional 5 cathode buffer prewetted Whatman blotting 
papers were put on the top. The air bubbles between the different layers were removed by 
rolling them out with a pipette. The lid was closed and a 1 kg weight was put on the top of the 
lid. Then an electric current of 350 mA was applied for 1 h. Finally, the blotted membrane 
was carefully removed and incubated in the blocking buffer overnight at 4
o
C. 
4.2.2.3.5 Immunostaining  
The blotted nitrocellulose membrane was transferred to a hybridization tube. Its upper surface 
holding the proteins was exposed to the inside of the tube to make the proteins accessible for 
the antibodies. The primary H800 rabbit anti-HBc-antibody (1:10000 in blocking buffer) was 
added to the tube containing the membrane and an incubation step was done in the 
hybridization oven at 25
o
C for 2 h. The membrane was washed then 3 times by incubation 
with washing buffer (PBS-T) for 15 min at RT and with shaking to remove the non-bounded 
antibodies. The washed membrane was reintroduced again into the hybridization tube and 
incubated with the secondary antibody (goat anti-rabbit-horseradish-peroxidase coupled 
antibody) in the hybridization oven at 25
o
C for 1.5 h. Three washing steps were done by 
incubating the membrane twice with washing buffer and once with PBS for 15 min at RT and 
with shaking to remove the free non bounded antibodies which may give false positive results. 
The detection of the blotted proteins was done by placing the membrane on a transparent foil. 
Then an adequate amount of freshly prepared Luminol Enhancer/Substrate Mixture (1:1 ratio, 
Roche) was added. Then the membrane was covered by another transparent foil and incubated 
in a dark place for 2 min to allow the action of the peroxidase enzyme on the substrate. 
Finally, the excess of the substrate and the air bubbles were squeezed out and the membrane 
was exposed to a film in a film cassette. The film was developed in the Curix 60 developer 
machine (Agfa) after different exposure time. 
4.2.2.3.6 Coomassie staining 
Proteins in SDS-polyacrylamide gels can be stained non-specifically using Coomassie 
Brilliant Blue stain. 
In this work, Coomassie Brilliant Blue (R-250) was used. The gel containing the denatured 
samples was immersed in 5 volumes of Coomassie Brilliant Blue staining solution and left at 
RT for 4 h with gentle shaking. The stained gel was then removed and incubated into an 
adequate volume of destaining solution at RT for 4-8 h with gentle shaking and with 
intermittent changing of the destaining solution with a new one. When the gel background 
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appeared clear a photo was taken. The gel was dried by immersing it in an adequate amount 
of gel drying solution for a few minutes. Then it was placed between 2 warm water prewetted 
cellophane papers. Finally, the air bubbles were squeezed out to avoid gel crashing and then 
the cellophane papers containing the gel were fixed into the gel drying frame (24×24 cm) 
which left in a vertical position for a few days till the gel was completely dry.   
4.2.2.4 Determination of protein concentration 
The DC-protein assay (Biorad) was used for the determination of the amount of expressed 
HBV capsids. The assay is based on the reaction of protein with an alkaline copper tartrate 
solution and Folin reagent. As with the Lowry assay, there are two steps which lead to 
colour development: The reaction between protein and copper in an alkaline medium, and 
the subsequent reduction of Folin reagent by the copper-treated protein. Colour 
development is primarily due to the amino acids tyrosine and tryptophan, and to a lesser 
extent, cystine, cysteine, and histidine. Proteins effect a reduction of the Folin reagent by 
loss of 1, 2, or 3 oxygen atoms, thereby producing one or more of several possible reduced 
species which have a characteristic blue colour with maximum absorbance at 750 nm and 
minimum absorbance at 405 nm. 
In this work, the standard to which the protein samples were calibrated was BSA. The 
procedure of the test was done according to the manufacturer Microplate Assay protocol. The 
OD of the samples was measured in a photometer at wavelength 655 nm and by using 
„Microplate Manager 4.0“(Biorad) software. 
4.2.3 In vitro  Selection of aptamers 
4.2.3.1 Filteration partition method 
Amicon Ultra-2 mL Centrifugal Filters (100 K) were used to separate the aptamer–HBV 
capsid complexes from the unbound ssDNAs. The basis of the methodology is the fact that 
HBV capsids (WT and mutant) have a much high molecular weight (~4 MDa) than aptamer 
(~17 KDa). So, the filtration using these filters with a cut off of 100 KDa will lead to the 
separation between the aptamer-capsids complex and free non bounded aptamers. To reduce 
the non–specific adsorption of nucleic acids to the filters, the filters were pre–treated with 
alkali as described (McENtee et al. 1980). The filters were filled with and soaked in 0.5 M 
KOH at RT for 20 min, then washed extensively with distilled H2O. The filters were filled 
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with and immersed in binding buffer (PBS) and left at RT for 45 min with gentle shaking and 
finally the old buffer was replaced by a fresh one. The filters were stored at 4°C. 
4.2.3.2 Selection procedure 
The selection method used in this work was SELEX with counter selection. The target molecule 
of in vitro selection was HBV WT capsids while the counter target was HBV- I126A mutant 
capsids. The binding buffer was phosphate buffered saline (PBS), pH 7.0. A ssDNA library (10 
nmol, about 6.0×10
15
 molecules) was used. Thirteen rounds of consecutive positive and 
negative selections were made (Fig. 3). To induce a sort of selective pressure, different 
concentrations of aptamers, WT capsids and mutant capsids were used throughout the different 
rounds of selection as well as different incubation times and different volumes of PBS during 
washing steps were used (Table 12). 
4.2.3.2.1 Snap cooling and pre-selection of aptamers 
To allow the aptamers to be folded into their 3 dimensional structures, the DNA library was 
dissolved in 100 μl binding buffer (PBS, pH 7), heated to 85°C for 15 min and immediately 
placed on ice for 15 min and then finally equilibrated at RT for 15 min. The renatured DNA 
was filtrated through the alkali pre-treated filter in the absence of target or counter target 
molecules to remove the matrix binders. 
4.2.3.2.2 Positive selection of aptamers 
The pre-selected aptamers were incubated with the target molecule (HBV-WT capsids) at 
RT. PBS were added to the aptamers/WT capsids mixture. After incubation the mixture was 
loaded onto an alkali pre-treated filter and centrifuged in a swinging bucket rotor at 4000 xg 
for 30 min at 25
o
C. The retained material (aptamers/WT capsids complex) was collected by 
inverting the filter and centrifugation at 1000 xg for 5 min at 25
o
C. The bounded aptamers 
were extracted by phenol/chloroform extraction (see 4.2.1.2.1) and then precipitated by 
using the QIAEX II Kit (see 4.2.1.2.3). The precipitated aptamers were resuspended in 
water and amplified by standard PCR using a forward non-biotinylated primer and a reverse 
biotinylated one (see 4.2.1.1.2). The PCR product was purified by the QIAEX II kit. Then it 
was mixed with streptavidin inducing an electrophoretic mobility shift for the preparation of 
ssDNA molecules (see 4.2.1.5). Three consecutive positive selection steps were done in the 
beginning of the selection process to reveal higher concentrations of the capsid best binders 
for the negative selection. 
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4.2.3.2.3 Negative selection of aptamers 
The positively selected aptamers were incubated with the counter target molecule (HBV-
I126A mutant capsids) at RT. PBS were added to the aptamers/mutant capsids mixture. 
After incubation, the mixture was loaded into an alkali pre-treated filter and centrifuged in 
swinging bucket rotor at 4000 xg for 30 min at 25
o
C. The non bounded aptamers which 
came into the flow through were directly precipitated using a QIAEX II kit after that 
amplified by PCR with reverse biotinylated primer. The PCR product was purified by the 
QIAEX II kit. Then it was subjected to streptavidin induced electrophoretic mobility shift to 
prepare ssDNA molecules to be used for the next round of selection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 17. General scheme of the SELEX with counter selection. 13 rounds of consecutive 
positive selection (against WT-HBV capsids) and negative selection (against I126A-HBV 
mutant capsids) were done. At the end aptamers having an affinity to the MBD of HBV were 
selected. Modified from http://www.springerimages.com/Images/LifeSciences/1-10.1007_978-1-61779-188-8_9-0.  
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Tabel 12: Conditions during 13 selection rounds. 
Round 1
st
, 2
nd
& 3
rd
    4
th
, 5
th
&6
th
  7
th
, 8
th
&9
th
  Last  4 
Aptamer amount 400 ng  400 ng  200 ng  100 ng  
WT - capsids amount  7 μg  3 μg  3 μg  1 μg  
Mutant capsids amount  3 μg  5 μg  5 μg  7 μg  
IT
1
 /WT-capsids  1 hour  1 hour  30 min  15 min  
IT / mutant capsids  30 min   30 min  1 hour  1 hour  
WR
2
 / + selection  1 ∕ 10  1 ∕ 10  1 ∕ 20  1 ∕ 20  
WR /- selection  1 ∕ 10  1 ∕ 10  1 ∕ 4  1 ∕ 4  
        1 IT is the incubation time 
        2 WR is the washing ratio 
4.2.3.2.4 Aptamer sequencing 
After 13 rounds of selection, the selected aptamers were cloned into the EcoRV site of 
pBluescript II KS (+). Purified plasmids were sequenced using primer VBAO05 (see 4.2.1.8). 
4.2.3.3 Aptamer secondary structure prediction 
Secondary structures of the selected aptamers were predicted by the Zuker algorithm (Zuker, 
2003), using Mfold (version 3.2, http://mfold.bioinfo.rpi.edu/cgi-bin/dna-form1.cgi) with 
conditions set up at 0.15 M NaCl and 25°C. 
4.2.4 Immunological & Biophysical Assays 
4.2.4.1 Immunoprecipitation assay 
The immunoprecipitation method can be used to qualitatively and quantitatively determine 
protein–nucleic acid affinities. The principle of this assay depends on the separation of the 
aptamer-protein complexes from the free aptamers by precipitating it using agarose beads on 
which polyclonal antibodies against the protein were fixed. 
4.2.4.1.1 Preincubation of agarose beads and antibody 
The protein G coupled agarose beads were undergoing coating by rabbit polycolonal 
antibodies against the HBV core protein. 25 μl of beads (Santa Cruz Biotechnologies) were 
washed 3 times with 1 ml PBS by centrifugation at 2500 rpm for 5 min at 4 
o
C. Then 1 μl of 
Mater ia l  and  me thods  
 
 
[55] 
undiluted rabbit anti-HBV core were added. The volume in the tube was filled up to ~800 ul 
with PBS to ensure proper mixing. The mixture was incubated on the sample rotator at 4 
o
C 
overnight to allow binding of the antibodies to the beads. In the morning, the coated beads 
were washed 3 times with PBS and resuspended into an adequate volume of PBS and left at 4 
o
C until usage. 
4.2.4.1.2 Incubation of aptamers and HBV capsids 
10 pmol of the pre-snap cooled selected aptamer (AO-01) were incubated with 0.1 pmol 
HBV-WT capsids in the binding buffer (100 μl) at RT for 1 h. 2 negative controls were made 
with the same conditions, the first one by incubating the pre-snap cooled selected aptamer 
(AO-01) with HBV-I126A mutant capsids, and the second one by incubating the pre-snap 
cooled randomly constructed aptamer (AO-0N) with the HBV-WT as well as with mutant 
capsids. To calculate the background of the assay, the same concentration of the pre-snap 
cooled aptamer (AO-01 and AO-0N) was incubated alone with the antibody coated beads. 
4.2.4.1.3 Immunoprecipitation 
The antibody coated beads were mixed with the aptamer∕capsid mixture and the volume in the 
tube was filled up to ~700 μl with PBS. The mixture was incubated on the sample rotator at 
RT for 2 hours to allow binding of the antibodies to HBV capsids. To remove non bounded 
aptamers, the mixture was washed 3 times with 1 ml PBS by centrifugation at 2500 rpm for 5 
min at 4 
o
C. Finally, the pellet was resuspended into adequate volume of water.  
4.2.4.1.4 Extraction of bounded aptamers 
The bounded aptamers were extracted from the capsids by two steps of phenol/chloroform 
extraction (see 4.2.1.2.1) and one chloroform extraction to remove any residues of phenol 
from the sample. Then the upper aqueous phase containing the aptamers was transferred to 
an eppendorf tube. The sample was then heated in a thermomixer to 85 
o
C for 15 min at 
350 rpm while the lid was open to evaporate any residues of chloroform that may affect 
the PCR reaction. To determine the percent of aptamer loss during this step, the same 
extraction steps were done for the same concentration of the pre-snap cooled aptamer 
alone. 
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4.2.4.1.5 Aptamers quantification 
The extracted aptamers were firstly diluted by PCR grade water and then quantified by real 
time PCR (see 4.2.1.9.2) using VBAO03 and VBAO04 as a primer set. 
4.2.4.2 HBV virion immunoprecipitation  
The cell culture supernatant of transfected HuH 7 cells was harvested and centrifuged for 
5 min at 4000rpm to pellet the cells. The supernatant (750 µl) was transferred into a new 
tube. Then anti-HBs antibody coated beads (see above) were added and the mixture was 
incubated overnight with rotation at 4°C. On the next day, the immunoprecipitate was 
washed 3 times with 1 ml of PBS. The supernatant was carefully removed and the pellet 
was resuspended in PBS. To degrade any free DNA molecule in the solution, DNAseI 
(Qiagen) was added with its specific RDD buffer and then the mixture was incubated at 
RT for 25 min. After that a washing step was performed using 1 ml of PBS. The virion 
DNA was liberated by incubating the mixture with proteinase K (17 nM) in the presence 
of its specific buffer at 56°C for 3h to allow destruction of the capsids. Finally, a 
phenol/chloroform treatment was done followed by ethanol precipitation to get DNA 
molecules which could be quantified by an HBV genome specific qPCR. 
4.2.4.3 Filteration assay 
The binding affinity of the aptamer–target complex can be determined by a filtration method. 
In this work, the pre-snap cooled selected aptamer (AO-01) and the negative control aptamer 
(AO-0N) were incubated with HBV WT and mutant capsids in the same concentrations as in 
immunoprecipitation assay (see 4.2.4.1.). The bounded aptamers were separated from the free 
ones as in the positive selection of the SELEX-last 4 rounds (see 4.2.3.2.2) and then recovered 
and quantified as in the immunoprecipitation assay. 
4.2.4.4 Determination of dissociation constant for the binding of aptamers 
to capsids 
The constant of dissociations (Kd) of the selected aptamers capsid complex were calculated by 
the immunoprecipitation method (see above). Different concentrations of the aptamers (from 
5 pM to 1 μM) and a fixed concentration of the HBV WT capsids (1 nM) were used. The 
obtained data were analyzed and then the Kd values of the different selected aptamers were 
estimated by the Sigma Blot 12.0 software program. 
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4.2.5 Cell Culture Techniques 
4.2.5.1 Cultivation of HuH7 
The cells which had been allowed to grow to a confluent monolayer were divided into several 
plates by splitting in appropriate ratios. Firstly, the cells were washed once with an adequate 
amount of 37°C warm PBS. After that the cells were trypsinized by covering the cells with 
trypsin/EDTA solution at RT for a few seconds. Then the trypsin/EDTA solution was 
removed and the cells were subsequently incubated at 37°C and 5 % CO2 with intermittent 
observation until the cells appeared to be detached from the plate. The detached cells were 
taken up in 6 ml 37°C warm growth medium (DMEM with 10 % FBS, 1x NEAA, 1x sodium 
pyruvate, 1 % Penicillin∕Streptomycin), diluted in the desired split ratio in the same media and 
transferred to new cell culture dishes. To maintain the cells in culture, they were split every 
four days with a ratio of 1:6. For transfection, the cells were seeded in 10 cm dishes or 6 well 
plates. They were either split 1:2 (10 cm dishes) or 1:15 (6 well dishes) the day before 
transfection. The total volume of growth medium in 10 cm dishes was 10 ml, in 6 well plates 
2 ml per well. 
4.2.5.2 Freezing of cells 
The plates with densely grown cells were trypsinized (see above). Then the cells were taken 
up in 900 µl warm FCS and transferred to a cryotube. Then, they were supplemented with 10 
% DMSO (100 µl) which is a cryoprotectant by adding it slowly and dropwise while swirling 
the tube to avoid an osmotic shock. The cells were firstly frozen in an ultra temperature deep 
freezer at -80°C. After a few days, they were transferred to liquid nitrogen where they were 
stored for unlimited time. 
4.2.5.3 Thawing of cells 
The frozen cells were thawed by immersing the cryotube into a water bath at 37°C until only 
a small frozen remainder was left. Then the cells were transferred to a 15 ml Falcon tube and 
10 ml of warm growth medium was added in a dropwise manner. Then the cells were settled 
by centrifugation at 1000 rpm for 5′ at 4°C. The supernatant was replaced by fresh growth 
medium and the cells were resuspended and distributed to two or three cell culture dishes. 
They were incubated at 37°C and 5 % CO2 until the cell layer was dense. Then they were 
split for at least two times and finally used for experiments. 
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4.2.5.4 Transfection of HuH7 
In this work, the transfection was done by using the Roche Fugene system (Fugene 6, 
Fugene HD or X-tremeGene HP) which forms complexes with DNA allowing the entrance 
of the vectors into the cells. 1 µg of DNA plasmid used for transfection of cells grown in 6 
well plates. When cotransfecting several DNA plasmids, they were used in the same 
molecular ratio making up 1 µg in total. The DNA was diluted in medium w/o any additives 
to reach 47 µl volume in total, and then 3 µl of Fugene reagent were added directly into the 
liquid without prior touching the tube wall with the pipette tip. The batch was mixed gently 
and incubated at RT for at least 40 min to allow the transfection complex to be formed. For 
transfection, preconfluent cells (~80 % density) split the day before were used and this  was 
done by splitting the cells in a ratio 1:20. Before transfection the cells had been washed 
once with PBS then the growth medium was replaced by 0.7 ml medium w/o any additives. 
The transfection complex was transferred dropwise and evenly onto the cells and the plates 
were swirled afterwards to ensure a proper distribution. The cells were then incubated for 6 
h at 37°C and 5 % CO2. Thereupon, the transfection medium was removed and the cell 
layer was washed once with PBS to remove remaining transfection complex. Two ml fresh 
growth medium was dispensed and the transfected cells were incubated for 3 days at 37°C 
and 5 % CO2. 
4.2.5.5 Harvest of supernatant 
The supernatant of transfected cells was harvested 3 days after transfection. It was transferred 
to 2 ml tubes and dead cells were pelleted by centrifugation at 13000 rpm for 10 min. 750 µl 
aliquots of the supernatant were preserved at -80°C until usage for immunoprecipitations. 
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5  Results 
5.1 Production and purification of recombinant HBV capsids 
The expression and purification of HBV WT capsids was done by Maira Bieringer during her 
master thesis (Bieringer, 2010). Her results are shown here again just for comparison with 
expression and purification of HBV I126A mutant capsids which was part of this work. 
5.1.1 Construction of expression vectors 
The DNA sequences for the C-terminally of codon 150 truncated core protein (delta-C) 
and its point mutant I126A (each of 455 bp nucleotide length) were present in the 
plasmids pRVHBV+ and pSVHBV1.1LE-I126A, respectively. They were amplified by 
conventional PCR using VBAO01 as a forward primer harbouring a start codon and a 
NCOI restriction site, and VBAO02 as a reverse primer containing a stop codon (TAA) 
and SALI restriction site (see 4.2.1.1.1). Both amplified sequences were doubly digested 
by the enzymes NCOI and SALI (see 4.2.1.7.1.2), gel extracted (see 4.2.1.4) and finally 
ligated with the doubly NCOI / SALI digested, gel extracted and purified T7 polymerase 
dependant expression vector pETM 13 (see 4.2.1.7.2).  
The resulting plasmids were tested by double restriction with NCOI and SALI of 10 
minipreparations. In addition, two samples of the expression vector exhibiting the stuffer 
gene (ABD, 834 bp), one without restriction and the other doubly restricted by NCOI and 
SALI were used as controls. All samples were electrophoresed in 1% native agarose gels 
containing EtBr to be visualized in the gel documentation system (see 4.2.1.3.1). In 
addition, to check the correct sequence of the PCR products, two samples of the 
miniprepared plasmids, one containing the gene for delta-C HBV WT core protein and the 
other containing the gene for delta-C HBV I126A mutant core protein, were sequenced 
using two primers: (1) The reverse primer VBAO02 allows the sequencing of the target 
sequence (455 bp) from bp 225 until bp 900. (2) The forward primer VBAO01 allows the 
sequencing of the target sequence from its beginning until bp 595 (see 4.2.1.8).  
The WT and I126A mutant constructs showed two bands in all 10 minipreparations (Fig. 
18; lanes: 1-10), the band of higher molecular weight refered to the backbone of the 
double digested vector (5252 bp) while the one of lower molecular weight had the same 
length as the target sequences that encoded for HBV WT and I126A mutant delta-C core 
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Fig. 18. Double, NCOI and SalI, restriction of DNA constructs encoding for HBV WT and 
its I126A mutant delta-C core protein. Double restriction of 10 HBV WT ligated constructs (A) 
and 10 HBV I126A- mutant ligated constructs (B) by NCOI and SalI enzymes showed a 5252 bp 
fragment (double restricted vector, pETM 13) and a 455 bp fragment (target gene sequence 
encoding for both HBV capsids). P1: NCOI and SalI enzymes double restricted pETM 13 
exhibiting a stuffer gene (ABD). P2: The non restricted pETM 13 vector. M1: Lambda marker 
and M2: 100 bp marker. 
proteins (455 bp). The doubly restricted expression vector exhibiting the ABD gene 
showed also two bands, the first was the same backbone of the double restricted vector 
(5252 bp) while the second band refered to the ABD sequence (834 bp) that encoded for a 
different protein, Actin Binding Domain (Fig. 18; lane: P1). The non-restricted expression 
vector showed a strong band of 6086 bp refered to the open circular form of the plasmid 
and another lighter band refered to the supercoiled form (Fig. 18; lane: P2). The 
sequencing revealed that the both target sequences were exactly as expected and contained 
no unintentional mutations. 
 
 
 
 
 
 
5.1.2 Capsid overexpression  
HBV WT and I126A mutant delta-C core proteins were successfully overexpressed in E.coli 
BL21 Star (DE3) pRARE2 cells. The cells were transformed with the expression vectors 
containing the gene sequences encoded for both, HBV WT and I126A mutant delta-C core 
proteins (see 4.2.1.7.3.3). In addition, a negative control was carried out by transforming the 
cells with the same expression vector (pETM 13) exhibiting the ABD gene that encoded for a 
different protein, Actin Binding Domain. The transformed bacterial cells were highly enriched 
in 500 ml culture media and simultaneously forced to express the proteins by using the 
Resul t s  
 
 
[61] 
inducer (IPTG) as described in 4.2.2.1. The over-expressed proteins were then liberated by 
lysing the cells using repeated freezing and thawing with 1 ml of lysis buffer (see 4.2.2.2.1).  
A preliminary test for the expression of HBV WT and I126A mutant delta-C core proteins, 
their molecular weight is nearly 16.8 KDa, was done and in comparison with the negative 
control protein (ABD, its molecular weight is 30.9 KDa) by electrophoresing a small 
volume of the supernatants of the lysed cells (1/100) in a 15% SDS gel to be stained by 
Coomassie Brillian Blue stain (see 4.2.2.3.6).  
The results (Fig. 19) revealed signals in the expected positions (16.8 KDa) for C-terminally 
deleted HBV WT core protein, the I126A mutant and the positive control indicating 
successful expressions of both HBV WT and its I126A mutant delta-C core proteins. The 
negative control showed a signal in the expected position for a different protein, actin 
binding domain (30.9 KDa). 
The capsids assembled from both expressed HBV core proteins, WT and I126A mutant, (240 core 
proteins, its molecular weight is nearly 4 MDa) were also immunodetected by western blotting.  
The supernatants of the lysed cells that expressed HBV WT delta-C core proteins, HBV 
I126A mutant delta-C core proteins and actin binding domain (as a negative control) were run 
in a 1% native agarose gel to be capillary blotted against a nitrocellulose membrane. Then the 
capsids were immunodetected by the anti-HBc antibody H800 (see 4.2.2.3.3/5).  
The results (Fig. 20) showed signals for both expressed HBV capsids, WT and I126A mutant 
capsids, parallel with the positive control while the negative control showed no signal 
indicating the successful assembly of the expressed HBV delta-C core proteins into capsids. 
 
  
 
 
 
 
 
 
 
 
 
 
Fig. 19. Coomassie Brilliant Blue stained E.coli expressed HBV WT and I126A mutant 
delta-C core proteins in 15% SDS gel. M: Page Ruler Plus Prestained Protein Ladder, WT: 
HBV wild type delta C, P: cell lysate harbouring HBV WT delta-C core proteins as a positive 
control, Mut.: HBV I126A mutant core proteins and N: negative control, Actin Binding 
Domain (ABD) protein.  
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Fig. 20. Immunoblotting detection of E.coli expressed HBV WT and I126A mutant delta-
C capsids in a 1% native agarose gel. 1&2: 0.01 and 0.1% diluted cellular supernatant 
containing HBV I126A mutant capsids, 3&4: 0.01 and 0.1% diluted cellular supernatant 
containing HBV WT capsids, N: negative control (ABD) and P: Positive control (WT HBV 
delta-C capsids). Exposure time was 5 seconds. 
 
 
 
  
5.1.3 Capsid purification 
5.1.3.1  Precipitation of proteins 
The total protein including the expressed capsids in the cellular lysates were precipitated by 
ammonium sulphate (see 4.2.2.2.2) to remove non protein like impurities and to concentrate 
the sample for the next step of the purification procedure, size exclusion chromatography. The 
delta-C core proteins of both, HBV WT and I126A mutant, were detected in the supernatant 
and the resuspended pellets after ammonium sulphate precipitation and also in the whole cell 
lysates before ammonium sulphate precipitation using Coomassie Brillian Blue staining in 
15% SDS gel.  
The results showed signals for delta-C core proteins (16.8 KDa) in the precipitate and also in 
the supernatant but its concentration appeared to be higher in the precipitate than in the 
supernatant (Fig. 21).   
 
 
 
 
 
 
 
 
 
Fig. 21. Coomassie Brilliant Blue stained HBV WT (lanes 1 to 3) and HBV I126A mutant 
(lanes 4 to 6) delta-C core proteins after ammonium sulfate precipitation in 15% SDS gel. M: 
Page Ruler Plus Prestained Protein Ladder, 1&6: whole cell lysate before precipitation, 2&5: cell 
lysate supernatant, 3&4: resuspended precipitated proteins, P: cell lysate harbouring HBV WT core 
proteins & N: negative control (ABD). 
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5.1.3.2 Size exclusion chromatography 
The HBV delta-C capsid has a large molecular weight (~ 4 MDa). This fact was used to 
purify the capsids by size exclusion chromatography using a column filled with Sephacryl S-
500 HR (GE Healthcare). The capsids should pass faster through the column matrix and 
should be collected earlier in the first fractions than the impurities with smaller molecular 
weight that were lodged in the matrix pores and were collected later (see 4.2.2.2.4.1).  The 
sample fractions  (each of 5 ml) that showed high absorbance at wave length 280 nm 
(fractions of higher protein content) were tested by Coomassie Brilliant Blue staining in 15% 
SDS gel (see 4.2.2.3.1/6) to define the fractions which harbour the highest concentration of 
the expressed capsids and with less impurities to be used afterwards.  
The results showed bands of both, HBV WT and its I126A mutant delta-C core proteins (~ 
16.8 KDa), with much less impurities. On the other hand, the whole fractions showed a 
similar non specific band of lower molecular weight (~ 14 KDa) which appeared to be 
correlated with the delta-C core proteins (Fig. 22).  
To check if the capsids were still intact without deassembly or degradation after the size 
exclusion chromatography, small amounts (1 μl of 1/100 dilution) from fractions containing 
the delta-C core proteins were electrophoresed in 1% native agarose gel and also into 15% 
SDS gel to be immunodetected by western blotting using anti-HBc (H800).   
All fractions in the native gel showed distinct signals in the same line as the positive controls 
indicating that there is no extensive capsid degradation. In the denaturing gel, the delta-C core 
proteins of both, HBV WT and its I126A mutant, showed the expected bands (~ 16.8 KDa) 
and the non specific bands which appeared after Coomassie Brilliant Blue staining (see 
above) disappeared completely indicating that these bands are non specific and not related to 
the expressed core proteins (Fig. 23).  
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Fig. 22. Chromatogram and Coomassie Brillian Blue staining of fractions with high core protein 
content after size exclusion chromatography during HBV capsid purification. After the size 
exclusion chromatography, both HBV WT capsids containing fractions (8-22) (A) and HBV I126A 
mutant capsids containing fractions (5-22) (B) showed high absorbance (blue lines) in the 
chromatogram, ~ 1000 and 300 mAU, respectively, and bands in the same position as the positive 
control (PK, HBV delta-C WT capsid) in 15% SDS polyacrylamide gel after the Coomassie blue 
staining. 0.1% of each fraction was used in PAGE. 
(A) 
(B) 
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Fig. 23. Western blot validation of HBV WT and I126A mutant delta-C capsids and their 
core proteins after size exclusion chromatography. Some fractions harbouring high 
concentrations of HBV WT and I126A mutant delta-C core proteins (fractions no. 12, 14, 16, 
18, 20 &22 in Fig. 22 A and B) showed signals in the expected positions as the positive control 
in both 1% native agarose gel (A) and 15% SDS gel (B). P: positive control (WT delta-C 
capsids) and N: negative control (ABD). 
 
 
    (A) 
 
 
    (B) 
 
5.1.3.3 Sucrose gradient ultracentrifugation 
After the size exclusion chromatography, the fractions 8 to 22 showed high concentrations 
of HBV WT core proteins (8:22) and the similar fractions showed high concentrations of the 
I126A mutant core proteins (5 to 22). They were pooled and then concentrated by using PD-
desalting columns (see 4.2.2.2.4.2) to be further purified by sucrose gradient 
ultracentrifugation (see 4.2.2.2.5) for further removing non specific proteins and other 
impurities which were still accompanied the capsids. Small amounts (1 μl of 1/100 dilution) 
of the collected fractions were immunodetected by western blotting in a 1% native agarose 
gel (see 4.2.2.3.2/3/5) to determine the fractions which contain the expressed capsids.  
The results showed positive signals for HBV WT and I126A mutant delta-C capsids in 
fractions 25 to 39 and fractions 24 to 39, respectively (Fig. 24). 
 
 
 
 
 
 
Fig. 24. Western blot detection of HBV WT and its I126A mutant delta-C capsids in different 
fractions after sucrose gradient ultracentrifugation. Fractions harbouring delta-C capsids of 
HBV WT (25 to 39) and its I126A mutant (24 to 39) showed signals in the expected positions as 
the positive control in a 1% native agarose gel. P: positive control (HBV WT delta-C capsids). 
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The fractions containing WT capsids (25 to 39) were pooled and the same also was done with 
the fractions containing I126A mutant capsids (24 to 39). Then the pooled fractions were 
filtered through a Millipore concentrator for removing the sucrose and also to concentrate the 
samples (see 4.2.2.2.3). To check the purity of the overexpressed capsids, small amounts from 
the solutions containing the purified capsids of both, WT and its I126A mutant, were 
electrophoresed in 15% SDS gel to be stained by Coomassie Brillian Blue. The results 
revealed that the impurities were greatly reduced. The signal of the purified WT capsids 
appeared higher in intensity than that of the I126A mutant capsids (Fig. 25).  
 
 
 
 
 
 
 
Fig. 25. Comparative Coomassie Brillian Blue detection of delta-C core proteins of both 
HBV WT and I126A mutant before and after purification in 15% SDS gel. M: Page Ruler 
Plus Prestained Protein Ladder, 1: 20 µl purified WT capsids, 2: 10 µl purified WT capsids, P1: 
whole cell lysate containing HBV WT delta-C capsids (positive control) and N: whole cell 
lysate containing ABD protein (negative control), 3: 20 µl purified I126A mutant capsids, 4: 10 
µl purified I126A mutant capsids and P2:  whole cell lysate containing HBV I126A mutant 
delta-C capsids (positive control). 
5.1.4 Determination of the concentration of purified capsids  
The concentrations of both purified capsids, HBV WT and I126A mutant, were measured by 
DC-protein assay (see 4.2.2.4). BSA was used as a standard. The final concentration of HBV 
WT capsids was 1.4 mg/ml. The total amount was 4.2 mg. The final concentration of HBV 
I126A capsids was 0.12 mg/ml. The total amount was 0.36 mg. 
 
 
Resul t s  
 
 
[67] 
5.2 In vitro selection of aptamers 
5.2.1 Aptamers quantification by real-time PCR 
The ability of quantifying aptamers from heterogenous ssDNA library of 55 nt length using real-
time PCR was tested. Five samples of the aptamers’ stock solution containing 103, 104, 105, 106 
and
 
10
7
 aptamers were amplified by real-time PCR using the primer set VBAO03 and VBAO04 
and with conditions described in paragraph 4.2.1.9.2. CT values/crossing points measured for the 
samples were plotted against the logarithm of the input amount of aptamers (Fig. 26A). To 
analyze the real time reactions, small volume (1/10) of the PCR product from each sample was 
electrophoresed through a 10% non-denaturing polyacrylamide gel, then the gel was immersed in 
a EtBr bath (100 μg/500 ml H2O) to visualize the DNA in the gel documentation system.  
The results revealed a linear fitting curve indicating that the PCR reaction was suitable for 
measuring the amount of the aptamers (Fig. 26A). In the gel, the PCR products showed 
signals with strong intensity in the expected position (55 bp). However, PCR by-products 
were detected especially in the samples containing 10
6 
and
 
10
7
 aptamers but with very low 
intensity (Fig. 26B). 
 
 
 
 
 
 
 
 
 
 
 
(A) 
(B) 
Fig. 26. Aptamers quantification by real-time PCR. (A) CT values/crossing points of five 
different aptamers amounts (10
3
-10
7
) show a linear curve against the logarithm of input amount 
of aptamers. (B) The real-time reactions of the aptamers’ five amounts after 10% PAGE. M: 
Marker, Gene Ruler 10 bp. 
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Fig. 27. Evaluation of filter alkaline treatment on the filteration efficiency. The 
efficiency of Amicon Ultra-2 mL Centrifugal Filters (100 K) against 55 nt length 
heterogenous ssDNA aptamers was greatly enhanced (~25 fold more) after the alkaline 
treatment using 0.5 M KOH. Mean values and standard deviations were calculated from 3 
independent experiments. *: P ≤ 0.05; **:P ≤ 0.01. 
5.2.2 Efficacy of alkaline pretreated filters 
Amicon Ultra-2 mL Centrifugal Filters (100 K) that were used during SELEX with counter 
selection were firstly alkaline treated using 0.5 M KOH (see 4.2.3.1). To check the effect of 
the alkaline treatment on the filteration efficiency against aptamers, 100 pmol (6.0×10
13
 
molecules) of the presnap cooled ssDNA library (see 4.2.3.2.1) were filtered through the 
alkaline pretreated filters and the same amount also filtered through non treated filters. Then 
the aptamer concentrations in both, filtrated and recovered solutions, were calculated by real-
time qPCR (see 4.2.1.9). The results revealed that the alkaline treatment of the filters has a 
significant effect on the filteration efficacy against ssDNA aptamers. Less than 5% of the 
aptamers that could pass through the alkaline non-treated filters and this percentage rose to be 
more than 97% after alkaline treatment (Fig. 27).   
 
 
 
 
 
 
 
 
The alkaline pretreated filters were also checked against the expressed HBV WT capsids to 
be sure that the filter matrix was still intact without any damage and also without any 
destructive effects on the capsids. A large amount of capsids (20 μg) were filtered through 
the alkaline pretreated filter, then the capsids were checked in the filterate by western 
blotting using anti-HBc antibody (H800) and also 0.1% of the recovery (the expected 
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Fig. 28. Western blot evaluation of the effect of filter alkaline treatment on HBV WT 
capsids. The signals of the different dilutions of the recovered capsids after filteration (1, 2, 3 
& 4) are of nearly the same intensity as the signals of the positive controls (P1: 20, P2: 10, P3: 
5 & P4: 2.5 ng).    
amount, 20 ng) was double fold serially diluted. Then the first four dilutions (the expected 
amounts 20, 10, 5 and 2.5 ng) were electrophoresed in 1% native agarose gel to be 
immunodetected by western blot. The results showed no capsids at all in the filterate while 
in the recovery the concentration of the capsids is nearly the same as the intial capsid 
concentration used in the experiment (Fig. 28). These results indicated that no damage or 
holes were performed in the filter matrix and also no harmful effects on the capsids were 
induced by the alkaline treatment of the filters. 
 
 
 
5.2.3 Optimization of aptamers PCR amplification 
The efficiency of PCR amplification of aptamers (library of heterogenous DNA sequences) 
was checked to find out if there are any differences from PCR amplification of the usual 
homogenous DNA templates.  
Six samples of two different concentrations of the ssDNA library (10 and 1000 pM) were 
amplified by conventional PCR using the primer set VBAO03 and VBAO04 (see 4.2.1.1.2) 
but with 3 different numbers of amplification cycles (35, 25 and 15 cycles). The six PCR 
products of each concentration were pooled together (300 µl), then concentrated and purified 
by a QIAEX II Kit (see 4.2.1.2.3). A small volume of each purified PCR product (1/10) was 
electrophoresed in 10% non-dentauring polyacrylamide gel then the gel was immersed in a 
EtBr bath (100 μg/500 ml H2O) to be visualized in the gel documentation system. 
The results revealed that with rising numbers of PCR cycles, the more and more PCR by-
products were produced, the higher was the possibility for losing the aptamer library. This 
was very obvious in the PCR product after 35 cylces as the aptamer PCR product (55 bp) was 
nearly lost (Fig. 29).  Concerning the difference in the initial concentrations of the aptamers 
used in PCR, non significant effects on the produced PCR products and by-products were 
observed.  
Resul t s  
 
 
[70] 
Fig. 29. Dependance of molecular weight fragment length of PCR products on the number 
of PCR cycles. After 35 PCR cycles, the PCR product appeared heterogenous with almost no 
product of 55 nt length using initial aptamer concentrations of 10 and 1000 pM, 1 & 2, 
respectively. By decreasing the number of PCR cycles to 25 (3 & 4) and 15 (5 & 6) cycles 
using the same initial concentrations, 10 and 1000 pM, respectively, the PCR by-products were 
reduced and nearly disappeared leaving more PCR products with the length of the original 
apamers. M: Marker, Gene Ruler 10 bp. 7: Negative control. 
 
 
 
 
 
 
 
5.2.4 SELEX with counter selection 
The snap cooled ssDNA library (10 nmol, ~ 6.0×10
15
 molecules) was initially preselected by 
filteration alone through the alkaline pretreated filter to remove all binders of the filter matrix. 
Then the concentration of aptamers which could pass through the filter was measured by a 
nanodrop machine and qPCR. Less than 2% of the aptamers was bound to the filter matrix 
and the ones which could pass (more than 98%) were recovered. To remove the huge amount 
of capsid non-binders, the preselected aptamers were used in three consecutive positive 
selections (see 4.2.3.2.2) against a constant amount of HBV WT capsids (7 μg, ~ 1012 capsids) 
without any PCR amplification in between.   
After the third positive selection, the recovered aptamers (~1 pmol, 6.0×10
11
 molecules) were 
divided into six aliquots to be amplified by conventional PCR using a non-biotinylated 
forward primer (VBAO03) and a biotinylated reverse primer (VBAO04) (see 4.2.1.1.2) 
followed by the purification of the pooled PCR products using a QIAEX II Kit (see 4.2.1.2.3). 
Then the purified dsDNA molecules were exposed to streptavidin, denatured by heat and 
separated by denaturing PAGE in the presence of 6 M urea to prepare ssDNA molecules (Fig. 
30A). To check the successful preparation of ssDNA molecules, small volumes (1/20) from 
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Fig. 30. Positively selected aptamers in 10% non-denaturing and denaturing (6 M urea) 
polyacrylamide gels. (A) The upper photo shows ssDNA molecules of both, aptamer stock 
solution a and the positively selected aptamer PCR product-streptavidin complex b, that formed 
sharp distinct parallel bands in the denaturing gel. The lower photo shows the excised gel piece 
containing the non biotinylated ssDNA aptamers to be recovered and used in the first SELEX 
round. (B) ssDNA aptamers from the aptamers’stock solution (P) and the recovered aptamers 
after 3 consequtive positive selections (1
st
, 2
nd
 & 3
rd
) showed smear like bands in the non-
denaturing gel indicating the high heterogenicity and multiple conformations of aptamers. M: 
marker, Gene Ruler 10 bp.  
the gel purified ssDNA molecules were electrophoresed in 10% non-denaturing 
polyacrylamide gel. The gel was immersed in a EtBr bath for 30 min to visualize the DNA in 
the gel documentation system (Fig. 30B). 
The figure shows the streptavidin induced an electrophoretic mobility shift after electrophoresis 
of the streptavidin/aptamer complex in 10% denaturing polyacrylamide gel containing 6 M 
urea. The ssDNA molecules formed a sharp distinct band (Fig. 30A) while in the non-
denaturing 10% polyacrylamide gel they formed to some extent a smear like band (Fig. 30B).  
 
 
 
 
 
 
 
 
The ssDNA aptamers in the excised gel piece were recovered by the crush and soak method 
and by a QIAEX II Kit (see 4.2.1.4.2). Their amount was calculated by a nanodrop machine 
and qPCR, the results revealed 1.4 µg and 4.2 × 10
13
 molecules, respectively. Theoretically 
and according to the molecular weight of the aptamer library (17 KDa), 1.4 µg should contain 
5 × 10
13
 aptamers. This small variance (16%) between the nanodrop and qPCR readings was 
owed to the efficiency of PCR amplification of heterogenous DNA sequences which seems to 
be lower than that of the homogenous templates. 400 ng (~ 1.5 × 10
13
 molecules) were used in 
the positive selection step (see 4.2.3.2.2) of the first SELEX round against HBV WT capsids 
(7 μg, ~ 1012 capsids). The amount of the resulting ssDNA aptamers was also calculated by a 
(B) (A) 
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Fig. 31. PCR products of thirteen rounds of 55 nt length aptamer selection against the 
MBD of HBV WT capsids. All rounds of aptamer selection (1
st
 – 13th) showed 55 bp bands at 
the same position as the PCR product of the aptamer stock solution (positive control, P) in 10% 
non-dentaturing PAGE.  The first rounds of selection (1
st
 – 4th) showed large (> 55 bp) and short 
(~ 45 bp) PCR by-products which gradually decreased and nearly disappeared in the last rounds 
of selection (10
th
 – 13th). M: marker, Gene Ruler 10 bp. 
nanodrop machine and qPCR, the results revealed 1.1 µg and 3.2 × 10
13
 molecules, 
respectively.  Then the same amount of aptamers used in the positive selection of the first 
SELEX round (400 ng) was used in the first negative selection (see 4.2.3.2.3) against HBV 
I126A mutant capsids (3 μg, ~ 4.5×1011 capsids). In the next rounds of selection the same 
procedure was followed but different concentrations of aptamers, WT capsids and mutant 
capsids were used as well as different incubation times and different volumes of PBS during 
washing steps were used (Table 12) to induce a selective pressure which could improve the 
selection of aptamers with high affinities.  
After each complete round of in vitro selection with counter selection and before the 
production of ssDNA molecules using the streptavidin induced electrophoretic mobility shift, 
a small volume of each PCR product (1/50) was electrophoresed in 10% non-denaturing 
polyacrylamide gel to be visualized in the gel documentation system (Fig. 31).  
The results revealed bands in the expected position (55 bp) indicating a successful aptamer 
selection. Because of the high heterogenicity of the aptamer library in the first rounds of 
selection (1-4), PCR by-products were more prominent than in the subsequent rounds. 
Throughout the subsequenct rounds of selection, the amount of PCR by-products declined 
gradually until they nearly disappeared at the last round. In addition, the aptamer band (55 bp) 
became sharper indicating the gradual reduction of library heterogenicity.  
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5.3 Characterization of selected aptamers 
5.3.1 Aptamer sequencing 
The ssDNA aptamers recovered from the final round (13
th
) of SELEX with counter selection 
were PCR amplified using a phosphorylated primer set (VBAO03 and VBAO04). The 
phosphorylated PCR product was purified by a QIAEX II Kit and an aliquot was ligated with 
EcoRV restricted, dephosphorylated and gel purified pBluescript II KS + (see 4.2.1.7.1.1, 
4.2.1.4.1 and 4.2.1.7.2). The ligated product was ethanol precipitated and introduced into 
E.coli DH10B cells (see 4.2.1.7.3.2).  Fifty clones were taken, enriched and subjected to the 
low scale plasmid preparation (see 4.2.1.7.4.1). Finally, the obtained plasmids were visualized 
in a 1% native agarose gel and sequenced (see 4.2.1.8).  
Out of 50 clones, 12 clones (24%) showed concatemers of aptamers which increased the 
number of sequenced aptamers to 73. Only 16 different variants were obtained. The lengths of 
the sequences ranged from 52 to 56 nucleotides. One selected aptamer (AO-08, 56 nt) was 
longer and 4 selected aptamers (AO-09, 11, 15 & 16) were shorter than the original length (55 
nt). Based on the sequence analysis, the first four aptamers represented more than 50% of all 
clones. The aptamer AO–01 was represented most frequently among the pool (~ 18%).  
Alignment of the selected aptamers revealed four distinct regions of conservation 
(…CG…N0,1,2,3,5,7...CCA…N0,2,5…TG…N0,2,3,5…TG…). These four conserved 
sequences were found in all aptamers except both shorter aptamers, AO-11 and AO-16, 
which missed only one TG of the conserved sequences. Eleven different aptamers (69%) of 
all sequences including the most frequent one (AO-01) contained no nucleotide between the 
first two conserved sequences. So they contained a pentameric consensus motif (CGCCA). 
Out of these eleven aptamers, six aptamers (38%) showed a GC nucleotide sequence 
between the last two conserved sequences generating a hexamer consensus motif 
(TGGCTG). This hexamer motif followed directly to the former pentamer consensus motif 
(CGCCA) forming an undecamer conserved motif (CGCCATGGCTG). Surprisingly, the 
best binder had also the same undecamer conserved motif but only one nucleotide (G) of the 
GC nucleotide sequence between the last two conserved sequences was replaced by a T 
nucleotide. The sequences of the aptamers AO-03 and AO-04 that have nearly the same 
frequency, showed great similarities as 10 consequent nucleotides (CCATTCCGTG) are 
present in both of them. Finally, it was obvious that the consensus motifs were located 
mostly at the same positions (closer to the 3’ end) in the original random region of selected 
aptamers (Table 13). 
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Tabel 13: Frequency and consensus sequences of selected aptamers. 
 
5.3.2 Secondary structure prediction 
Secondary structures of the selected aptamers were predicted by the Zuker algorithm (Zuker 
2003), using Mfold (version 3.2) with conditions set up at 0.15 M NaCl and 25°C.  
The potential secondary structures revealed that five variants (AO–01, AO–02, AO–03, 
AO–04 & AO–10) could be folded into very  similar helix like structures with a large bulge 
close to the 3’ fixed sequence. For the other aptamers different folds were predicted. 
However by forcing the conserved sequences within these variants to be single stranded 
using corresponding constraint in the software program, they could be folded into structures 
very similar to the proposed structure of AO–01 (Fig. 32). In all variants, the second 
consensus sequence (CCA) appeared mostly closer to the 5′  end of the bulge and the first 
consensus sequence (CG) formed the stem 5′  of the bulge while the two last consensus 
sequences (TG) are mostly positioned at end of  the large bulge (Fig. 32). 
Aptamer Random sequence No. 
Frequency 
(%) 
L 
(nt) 
AO-01 CACACGCGAGCCGCCATGTCTGGGC 13 17.8 25 
AO-02 GGGACCGCAGAAGACCACATGTGCC 11 15.1 25 
AO-03 GGGACGGCCCGCCATTCCGTGTGGC 7 9.6 25 
AO-04 GTCGACGCGCCCATTCCGTGGGGTG 6 8.2 25 
AO-05 GGCACACAACGTCGCCATGGCTGTG 4 5.5 25 
AO-06 CCCACGCAACGGCGCCATGGCTGTG 4 5.5 25 
AO-07 GCGTCGGCGCGCGCCATTGTGGTGC 4 5.5 25 
AO-08 GGGCAGGGTCGACCGCCATGGCTGTG 4 5.5 26 
AO-09 GGCACAAACGCGCCATGGCTGC 4 5.5 22 
AO-10 GCCAACGACGGGCCGCCATGGTCTG 3 4.1 25 
AO-11 GGCACAAACGCGGGCCATCCATGC 3 4.1 24 
AO-12 GGCACCCAACGCCCCCATGGGTGTG 2 2.7 25 
AO-13 GGGCAGGGTCGACCGCCATGGCTGG 2 2.7 25 
AO-14 CCGAGGGGCAACGGCGCCATGGCTG 2 2.7 25 
AO-15 CATAACGTTGCCCCCCATGTGTTG 2 2.7 24 
AO-16 GGCAGCCTCGACCCCCCATGGC 2 2.7 22 
Total 73 100  
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Fig. 32. Potential secondary structure of aptamer AO–01. Positions 1–15 and 41–55 are the 
primers sequences. The conserved nucleotides are green and red colored and serrounded by 
circles. All aptamers containing the conserved motif could be folded into similar secondary 
structures (after removing the possible base pairing of their conserved sequences) based on the 
folding algorithm of Zuker. 
 
 
5.3.3 Binding characteristics 
5.3.3.1 Binding affinity and specificity 
The binding affinity of aptamer AO-01 (showed the highest frequency) to the HBV WT 
capsid was evaluated in comparison to its binding affinity to the HBV I126A mutant 
capsids. The presnap cooled aptamers (10 pmol) were incubated with the capsids (0.1 pmol) 
in binding buffer (PBS, 100 μl) at room temperature for one hour. For separating the free 
aptamers from the bounded ones, two different techniques, immunoprecipitation and 
filteration, were used. In the immunoprecipitation technique, the volume of the 
aptamer/capsid mixture (100 μl) was rised by binding buffer to 700 μl. The mixture was 
incubated with anti-HBc antibody coated agarose beads for the immunoprecipitation (see 
4.2.4.1). In filteration technique, the volume of mixture was raised by binding buffer upto 2 
ml and filtered through the alkaline pretreated filter (see 4.2.4.3). Finally, the bound 
aptamers were recovered by phenol / chloroform extraction, precipitated using a QIAEX II 
Kit (see 4.2.1.2.1/3) and their concentration were defined using a nanodrop machine and 
qPCR. As a negative control, the binding affinity of an aptamer with random region (AO-
0N) against both capsids was evaluated using the same concentrations and conditions as 
with aptamer AO-01. The background was calculated in both immunoprecipitation and 
filteration assays by either incubating the same amount (10 pmol) of the presnap cooled 
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aptamers (AO-01 and AO-0N) with the anti-HBc antibody coated beads directly for one 
hour or by filtering them directly through the alkaline pretreated filters, respectively. Then 
they were recovered by the same procedure and their amount was calculated by a nanodrop 
machine and qPCR. 
The background of both immunoprecipitation and filteration assays showed relatively low 
binding of the presnap cooled aptamers AO-01 and AO-N with the anti-HBc antibody coated 
beads (appr. 1%) and also with the filter matrix (appr. 2%), respectively. The results revealed 
that the number of AO-01 aptamers that bounded to WT capsids was 69.4 and 41.8 aptamers 
per capsid while the number bound to I126A mutant capsids was 12.8 and 12.5 aptamers per 
capsid were measured by filtration and immunoprecipitation assays, respectively. On the other 
hand, the number of AO-N aptamers that bound to WT capsids was 6.5 and 2.9 aptamers per 
capsid while the number of bound AO-N aptamers to I126A mutant capsid was 4 and 3.6 
aptamers per capsid were calculated from filtration and immunoprecipitation assays, 
respectively (Table 14). The ratio of WT capsid bound negative aptamers (AO-N) to I126A 
mutant capsid bound aptamers was 0.8 and 1.6 fold (immunoprecipitation and filteration 
assays, respectively) indicating that there was only a low degree of unspecific binding of the 
negative aptamer to both capsids. The ratio of aptamer AO-01 bound to WT and I126A 
mutant capsids was 3.3 and 5.4 (immunoprecipitation and filteration assays, respectively) 
indicating that there was a specific binding of aptamer AO-01 to WT capsids (Fig. 33). 
Tabel 14: Calculation of the number of bound aptamers per WT and I126A mutant 
capsid by filtration and immunoprecipitation (IP) partitioning techniques. 
 
 
 
 
 
 
 
 
 
 
 
 
 
              Aptamer  
HBV capsid 
AO-01 AO-N 
filtration IP filtration IP 
WT 69.4 ± 11.2 41.8 ± 8.2 6.5 ± 2.2 2.9 ± 0.8 
mutant 12.8 ± 2.30 12.5 ± 1.2 4.0 ± 1.7 3.6 ± 2.1 
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Fig. 33. Binding affinity and specificity of aptamer AO-01 to HBV WT delta-C capsids. 
The binding ratio of aptamer AO-01 to HBV WT and I126A mutant capsids was 3-4 fold more 
than that of the negative aptamer (AO-0N) using two different partitioning techniques, the 
filteration and immunoprecipitation. The binding affinity of the aptamer AO-01 to WT capsids 
was 3.3-5.4 fold more than its binding affinity to I126A mutant capsids. Mean values and 
standard deviations were calculated from 3 independent experiments. **: P ≤ 0.01; ***:P ≤ 0.001. 
 
 
 
 
 
 
 
 
 
 
5.3.3.2 Kd determination 
The Kd values of the four aptamers that had showed the highest frequencies (> 50%) after 
SELEX (AO-01, 2, 3 & 4) were determined against HBV WT and I126A mutant capsids, 
using the immunoprecipitation assay and the results were determined and analyzed by the 
SigmaPlot 12 software program (see 4.2.4.4, Fig. 34 and Fig. 35).  
The results revealed that the Kd value of the aptamer AO-01 against WT capsids (180 ± 82 
nM) was at least 7 fold less than its Kd value against I126A mutant capsids (1306 ± 503 
nM) and also it was the lowest among the Kd values of the four aptamers (Table 14). 
Tabel 15: Dissociation constants (Kd) of four selected aptamers against HBV WT and 
I126A capsids. 
  
     
 
 
Aptamer 
Frequency 
(%) 
Kd / WT 
(nM) 
Kd / Mut 
(nM) 
AO-01 17.8 180 ± 82 1306 ± 503 
AO-02 15.1 335 ± 96 1041 ± 449 
AO-03 9.6 284 ± 169 925 ± 426 
AO-04 8.2 369 ± 285 780 ± 452 
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Fig. 34. SigmaPlot global curve fitting to measurements for determining Kd of best binder 
AO-01 against HBV WT and I126A mutant capsid. Increasing the concentration of the 
aptamer showed reproducible binding to a fixed concentrations of HBV WT and mutant capsids 
but the binding ratio to WT capsids (A) was much higher than that to the mutant one (B) and 
this could be easily observed in the merge of the figures (C). Mean values and standard 
deviations were calculated from 3 independent experiments.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) (B) 
(C) 
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Fig. 35. Comparative SigmaPlot global curve fitting to measurements for determining Kd 
values of four selected aptamers against HBV WT and I126A mutant capsids. The binding 
ratios of the four selected aptamers to WT capsids was correlated with the aptamer frequency 
and this could be seen in the best binder AO-01 (of the highest frequency) which showed the 
highest binding ratio to WT capsids (A). On the other hand, the binding ratios of the four 
selected aptamers to the mutant capsids showed no marked correlation with aptamer frequency 
and also no great variance (B). Mean values and standard deviations were calculated from 3 
independent experiments and they are not shown here for better visualization. 
(A) 
(B) 
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5.4 In vitro inhibition of nucleocapsid envelopment  
The inhibitory effect of the selected best binder (AO-01) on HBV capsid envelopment was 
preliminary tested in HuH-7 cell culture. In order to produce HBV virions in HuH-7 cells, the 
cells were transiently transfected with three trans-complementary plasmids: (1) 
pSVHBV1.1LE- contains the HBV genome carrying two stop codons in the surface protein 
ORF. Therefore it can not express the envelope proteins and consequently can not induce 
production of virions, (2) pSVBX24H carrying the gene for SHBs and (3) pSV45-57 
harbouring genes encode for LHBs besides MHBs and SHBs.  
The HuH-7 cells were transfected (see 4.2.5.4) by five different mixes. Three of them (P, S & 
N1) contained the same amount (1 μg, 1:1:1 molar ratio) of the three plasmids 
(pSVHBV1.1LE-, pSVBX24H and pSV45-570). The first sample (P) had only these 3 
plasmids as a positive control, the second one (S) had the pre-snap cooled best binder AO-01 
(1 μg) beside the three plasmids, the third one (N1) had the pre-snap cooled negative aptamer 
AO-0N (1 μg) together with the three plasmids as a first negative control, the fourth one (B) 
had pSVHBV1.1LE- only which could not produce virions alone as a background and the 
fifth one (N2) had no constructs at all as a second negative control. The cell supernatants were 
collected 3 days post-transfection. The secreted virions were immunoprecipitated with 
antibodies against SHBs and their genomes were recovered to calculate their concentrations 
using an HBV genome specific qPCR (see 4.2.4.2 & 4.2.1.9). The inhibition of HBV 
replication was calculated by the following equation: 
 
 
Nearly no signal was detected in the negative control (N2). The background (B) showed 
relatively high readings (nearly the half of the positive control). The results revealed that the 
best binder AO-01 (S) could inhibit virion secreation by 47.1 – 61.9 % while the negative 
aptamer AO-N (N1) show non significant degree of inhibition (< 5.5 %) (Fig. 36).  
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Fig. 36. The inhibitory effect of the best binder AO-01 on HBV virion production in 
HuH-7 cells. (S) The number of HBV virions secreted from cells cotransfected with the best 
binder besider AO-01 and the three HBV trans-complementary plasmids pSVHBV1.1LE-, 
pSVBX24H and pSV45-57. (P) The number of HBV virions secreted after transfection by the 
three HBV trans-complementary plasmids. (N1) The number of HBV virions secreted after 
cotransfection with the negative aptamer AO-0N and the three HBV trans-complementary 
plasmids. (B) The number of HBV virions secreted after transfection by the plasmid 
pSVHBV1.1LE- (N2) The number of HBV virions secreted after adding the transfection 
reagent on cells without any DNA molecules. The number of the secreted virions were 
measured 3 days post-transfection. Mean values and standard deviations were calculated from 4 
independent experiments. 
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6  Discussion 
In this project in vitro selection with counter selection was used to identify ssDNA aptamers 
that could bind to the MBD of HBV capsid to inhibit its interaction with the MD of the L 
envelope protein and consequently inhibits the HBV capsid envelopment and virion release. 
For in vitro selection with counter selection, both WT and I126A mutant HBV capsids were 
successfully expressed and purified to be used as a target and a counter target, respectively. 
The selected aptamer of the highest frequency (AO-01) bound to the target with a Kd of 180 
nM in a very specific manner. Sequence alignment of selected aptamers revealed four 
conserved sequences (CG, CCA, TG & TG) among all high–affinity aptamers. These 
consensus sequences could be folded into a large bulge with a stem like structure by 
secondary structure prediction. In cell culture, the selected best binder (AO-01) could 
inhibit HBV virion production by at least 47 %. 
6.1 E.coli HBV expressed capsids 
To select ssDNA aptamers having high binding affinities to the MBD of HBV capsids, it 
was essential to over-express two HBV capsids, the WT and an envelopment-deficient 
mutant. As the capsid mutant the version I126A carrying a point mutation in the MBD 
residues. This mutant forms comparable amounts of capsids relative to the WT but can not 
be enveloped (Ponsel and Bruss, 2003). For assembly of the HBV capsid, the N-terminal 
140 amino acids of the core protein are sufficient (Birnbaum and Nassal, 1990). The 
arginine-rich C terminus of the HBV core protein is not believed to be directly involved in 
capsid formation because core subunits without the basic C terminal region still assemble 
into shells. Furthermore, it was proposed that the C terminal region is important mainly for 
pregenome encapsidation (Gallina et al., 1989; Nassal, 1992; Zlotnick et al., 1997). No 
morphological differences can be observed between HBV capsids that were assembled in E. 
coli and the authentic capsids from virions of infected liver (Kenney et al., 1995).  
The C terminal region has binding capability to nucleic acids. Therefore, to reduce the 
possibility of non-specific binding of aptamers, C terminal deleted HBV core proteins of 
both WT and mutant I126A were decided to be expressed in E. coli. The used expression 
plasmid was controlled by the lac operon which suppresses the expression of the desired 
protein (HBV core protein) until IPTG is added. After adding IPTG during the mid-log 
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phase of growth, HBV core protein could be successfully expressed in large amounts (see 
5.1.2) (Wynne et al., 1998).  
The Coomassie blue staining of both WT and I126A mutant core proteins in 15% SDS-
denaturing gels after treatment with a reducing agent (DTT) could not distinguish between 
them. This is owed to the molecular weights of their delta-C core derivatives, 16847 and 
16805 Daltons, respectively, which showed a narrow difference (only 42 Daltons). 
Moreover, the isoelectric point of both core proteins became nearly similar by the action of 
SDS that is present in both, denaturing gel and running buffer. Therefore, they produced 
nearly parallel bands in the gel (see Fig. 19). Under non-denaturing conditions in native 
agarose gels, however, a difference in the position of the band after electrophoresis was 
observable (see Fig. 20). This difference is propably not due to the difference in the 
molecular weight which is still relatively small (7560 Da for a 4 MDa particle), but the 
difference might be due to changes in the isoelectric point.    
6.2 Purification of the expressed capsids 
Throughout the purification steps, the immunodetection of both purified WT and mutant 
I126A capsids in 1% native agraose gels showed two bands (see Fig. 23/24). This is 
probably owed to different conformations of HBV capsids, T=3 and T=4. Two 
conformations of HBV capsids, T=3 and T=4, composed of 180 and 240 core proteins, 
respectively, can be found not only in the natural liver infections but also in the laboratory 
setting (Cohen and Richmond, 1982; Kenny et al., 1995). In this project, both WT and 
I126A mutant capsids consist of truncated core protein (149 aa in length). However, they 
could produce both conformations, T=3 and T=4, which is the same as the results described 
in the literature (Newman et al., 2003). Newmann and his colleagues showed that HBV 
capsids constructed from either full-length (183 aa) or truncated (149 aa) core proteins can 
produce the T=3 and T=4 conformations with a difference in their molecular weighs by at 
least 1 MDa which could be easily detected in the native agarose gel. 
After purification of the both capsids by chromatography, the preparations containend high 
concentrations of the capsids with low amounts (nearly disappeared) of impurities except 
for a protein of approximaterly 14 KDa molecular weight (see Fig. 22). The Coomassie blue 
staining of all purified fractions in 15% SDS polyacrylamide gels revealed this protein. This 
protein was not detected by the immunodetection of the purified fractions in the denaturing 
gel using anti-HBc (see Fig. 23) indicating that it is a non specific protein and is not 
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correlated to the HBV core protein. Another possibility is that this 14 KDa protein is a 
fragment of the core protein loosing the epitope. Therefore, additional purification step, 
sucrose gradient ultracentrifugation, was used to remove this protein.  
6.3  Optimization of the in vitro selection protocol 
There are many different types of in vitro selection of aptamers. The choice of a suitable in 
vitro protocol for selecting aptamers against a target molecule depends largely on the target 
properties and the requirements of selected aptamers. In this project, the target is a small 
domain (MBD, 2.3 KDa) present numerously on the surface of a large particle (HBV 
capsid, 4 MDa). Moreover, there is a mutated form of the HBV capsid carrying only a point 
mutation (I126A) in the target domain inhibiting its binding to another protein (MD of L 
protein) which is an essential step in HBV capsid envelopment (Bruss, 2007). In vitro 
selection with counter selection is a specific type of SELEX depending on sequential steps 
of a positive selection against a protein containing the target epitope and a negative 
selection against a mutant protein devoid of this epitope or contains a mutated functionless 
one (Andreola et al., 2001). Thus, in this project, the method of counter selection was used 
for selection of aptamers against the MBD of HBV capsid (see Fig. 17).   
The type of oligonucleotide library is an important aspect for the selection process. There 
is no difference between DNA and RNA aptamers in terms of affinity and specificity. 
However, DNA aptamers have certain advantages over RNA aptamers: (1) DNA aptamers 
are more stable than RNA aptamers in a broad range of conditions including biological 
fluids, which improve their effects in different clinical applications. (2) The in vitro 
selection procedure for DNA aptamers is much faster and easier than that for RNA 
aptamers (Gold et al., 1995a; Hermann and Patel, 2000). Therefore, a ssDNA library was 
chosen instead of a RNA library in this work.  
In general, the selected specific binders in each round of the in vitro selection are 
accompanied with a number of non-specific binders. These non-specific binders are selected 
either by their non specific binding to the target by electrostatic interactions alone or due to 
the effect of incomplete separation between bounded and non-bounded sequences which is 
called in another term as background partitioning (Vant-Hull et al., 1998; Gerland et al., 
2002). Therefore, multiple rounds of selection are generally needed in order to eliminate 
non-specific binders. The number of selection rounds depends largerly on the method of 
partitioning used in the experiment. For example, to complete the entire selection process in 
Discuss ion  
 
 
[85] 
which nitrocellulose membranes are used, 12-15 cycles are usually required. After that the 
selected molecules can be cloned into an appropriate vector and sequenced (Gopinath, 
2007). In this project, the partitioning step was carried out by filteration using nitrocellulose 
membranes. Thus, 13 rounds of in vitro selection with counter selection were performed.  
One problem facing the usage of nitrocellulose membranes during the partitioning step is 
that these membranes can adsorb nucleic acids to a large extent. The alkaline treatment of 
these membranes could greatly reduce the non–specific adsorption of ssDNA aptamers 
improving the filtration efficiency (see Fig. 27) (McENtee et al. 1980). Moreover, the pre-
selection step against the membrane matrix removed the filter matrix binders from the 
ssDNA library. Therefore, almost 98% of the sequenced variants obtained after thirteen 
cycles of in vitro selection with counter selection usually turned out to be target binders 
(Gold et al., 1995). 
For the in vitro selection, a chemically synthesized ssDNA library was used directly without 
PCR amplification. A different protocol was applied by some researchers on the aptamer 
library before starting the selection process. This protocol depends on PCR amplification of 
the random library in a large scale before initiating the selection process in order to 
eliminate damaged DNA synthesis products, which can not be amplified by PCR. However, 
the main drawback of this protocol is the possibility for losing some of the target–binding 
sequences in the original library due to the variance of PCR efficiency (Marshall & 
Ellington 2000; Dubertret et al., 2001). In the denaturing gel, the oligonucleotides in 
original ssDNA library showed the expected length (see Fig. 30A). Thus, a library with 
about 6×10
15
 sequences was used directly in the first round of selection. 
For the overall in vitro selection procedure to be efficient, PCR amplification of the selected 
aptamers within the rounds of selection must be highly efficient. Fundamental differences 
could be detected between PCR amplification of homogeneous DNA templates and PCR 
amplification of random DNA libraries. In the PCR reaction, the homogenous DNA 
template is producing PCR products until primers are exhausted (plateau phase) while for 
the random DNA library the production of PCR products stops when PCR primers are still 
in excess. At this point PCR products convert rapidly to by-products and virtually disappear 
after a few additional PCR cycles. The conversion of PCR product to by-product is mostly 
induced by product-product hybridization within the heterogenous DNA libraries (Musheev 
and Krylov, 2006). It was confirmed that, by increasing the number of PCR cycles, the by-
products were accumulated and their amounts increased gradually untill they dominated the 
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PCR products and the 55 bp long molecules nearly disappeared (see Fig. 29). Therefore, 15 
PCR cycles were used. This showed the lowest concentration of PCR by-products in this 
project. 
Streptavidin induced electrophoretic mobility shift offered an efficient and fast method for 
ssDNA preparation. The partitioning of biotinylated-DNA/streptavidin complex and the 
band purification of non-biotinylated ssDNA can be combined in a single step resulting in 
higher yield with less effort (see Fig. 30A). This technique was also suggested in the 
literature (Pagratis, 1996).  
A risk during the in vitro selection process is the elimination of the strongest binders from 
the initial random pool in the first selection steps because the concentration of the 
strongest binders is extremely low at this time. Since the fraction of strong binders 
increases with the number of rounds, the risk of eliminating them is getting lower during 
the later rounds of the procedure. So, a higher protein to aptamers ratio should be used in 
the first rounds of selection, but then in the subsequent rounds this ratio should be reduced 
gradually (He et al., 1996). Therefore, in the positive selection, a higher WT 
capsid/aptamer ratio was used in the first 3 selection rounds and this ratio was reduced 
gradually untill it reached the lowest level in the last 4 selection rounds. On the contrary, 
in the negative selection the ratio of I126A mutant capsid/aptamer was increased 
gradually untill it reached the highest level in the last 4 selection rounds. Moreover, in the 
positive selection and contrary to the negative selection, the incubation time for the 
aptamer capsid binding was reduced gradually throughout the subsequent selection rounds 
until it reached the lowest level in the last 4 rounds. In addition, in the positive selection 
and contrary to the negative selection, the volume of the washing buffer was increased 
gradually throughout the subsequent selection rounds untill it reached the highest level in 
the last 4 steps (see Table 12). The aim of this procedure was to decrease the stringency of 
selection in the early rounds of the experiment, but to increase it later in the experiment, 
when the strongest binders are present in larger quantity. Such a procedure could induce a 
selective pressure and reduces the risk of losing the best binders during the in vitro 
selection (see Fig. 31). This procedure was also proposed by numerical simulations (Irvine 
et al., 1991). 
Discuss ion  
 
 
[87] 
6.4 Structural features of the aptamers  
The aim of the in vitro selection is to identify the strongest binders for a given target 
molecule. Usually, the selection process reveals more than one selected aptamer. By 
comparing their sequence it is often possible to define a consensus sequence present in all 
or a major fraction. The existence of consensus sequence/s among the selected 
oligonucleotides is an indication for the successful selection. Usually, an oligonucleotide 
binder that is far from the consensus shows sequence-independent interaction with the 
target protein (Winter et al., 1981). In this work, sixteen variants were selected, and all 
showed four conserved sequences (CG, CCA, TG & TG) which indicated a successful 
selection. Four out of the sixteen selected variants showed nucleotide lengths different 
from the initial library (55 nt length) (see Table 13). This owed to insertions and deletions 
within the randomized region that presumably arose during PCR amplification or all of 
these variants were present already in the original library. 
In principle, the interactions of proteins with single-stranded oligonucleotides are more 
complex than protein-dsDNA interactions. This is due to the fact that interactions of 
proteins with single-stranded oligonucleotides depend largely on nucleic acid secondary and 
tertiary structures (Jones et al., 2001). This was also supported by Nagai who showed that 
the proteins generally tend to interact with RNA in locations where the RNA forms 
secondary structure elements such as stem-loops and bulges (Nagai, 1996). In this project, 
the conserved sequences among all selected variants could be folded into a common motif 
of a bulge like structure by secondary structure prediction. 
6.5 Binding affinity and specificity of the aptamers  
After a certain number of in vitro selection rounds are performed, the affinity of the selected 
binders reaches an upper limit. The upper limit is determined by the affinity of the strongest 
binder in the initial random library. At the upper limit, most of the sequences in the selected 
pool will consist of the strongest binders (Vant-Hull et al., 1998; Djordjevic and Sengupta, 
2006). In this project, four selected aptamers (AO-01, AO-02, AO-03 and AO-04) 
represented more than 50% of all sequenced clones. The aptamer AO–01 was represented 
most frequently among all selected sequences (~ 18%) (see Table 13). Therefore, the 
constant of dissociation (Kd) of these four selected aptamers to WT capsids was measured. 
Furthermore, to evaluate the specific binding of the selected aptamers to WT capsids, the Kd 
values of the four selected aptamers to I126A mutant capsids were also tested. The Kd 
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values of the four selected aptamers to WT capsids were correlated to a large extent with the 
aptamer frequency. E.g. the aptamer AO-01 had the highest frequency (~ 18%) and showed 
the lowest Kd to WT capsids (180 nM). On the contrary, the Kd values of the four selected 
aptamers to the mutant capsids showed no marked correlation with aptamer frequency and 
also no great variance (see Fig. 35 and Table 13). This indicates that the selected aptamers 
have specific binding affinity to WT capsids rather than to the mutant capsids. The I126A 
mutant capsid is the same as the WT capsid except only for its MBD. So, the selected 
aptamers have specific binding affinities to the MBD of HBV WT capsids.   
In addition, the binding affinity of aptamer AO-01 to both WT and I126A capsids was 
tested in comparison with a negative aptamer (AO-N) which has not any of the four 
conserved sequences. The binding ratio of aptamer AO-01 to HBV WT versus I126A 
mutant capsids was around 4 whereas the ratio of the negative aptamer (AO-0N) was around 
1 measured by two different partitioning techniques, immunoprecipitation and filteration. 
So, the random oligonucleotide did not distinguish between WT and mutant capsids while 
aptamer AO-01 preferentially bound to the WT capsid. In general, during the evaluation of 
aptamer AO-01 binding affinity to WT capsids, the filteration partitioning technique 
showed higher readings than the immunoprecipitation technique (see Table 14). This is 
owed to the background of the partitioning which seems to be higher for the filteration than 
for the immunoprecipitation method. Therefore, the immunoprecipitation technique was 
used during the Kd determination of selected aptamers. 
6.6 Inhibition of HBV nucleocapsid envelopment in HuH 7 cells 
To test the inhibitory potential of the best binder AO-01 on HBV release in HuH 7 cells, it 
was essential to monitor virions in the supernatant of transfected cells. One method with 
relatively strict constraints and drawbacks to achieve this purpose. This method was created 
by Landers and his colleauges and called endogenous polymerase reaction (Landers et al., 
1977). It depends on the in vitro completion of the gap in the incomplete double stranded 
viral DNA genome which is contained in mature capsids by the viral polymerase which is 
packed within the same capsid using radioactive labelled nucleotides. These radioactively 
labelled genomes purified from the capsids of secreted virions can be easily visualized after 
gel electrophoresis by autoradiography. The usage of radioactive substances was considered 
as the major disadvantage of this method. Moreover, the measurement of HBV 
concentrations by e.g. southern blotting of the viral genome is relatively unsensitive and 
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hampered by the large amount of plasmids carrying HBV sequences in the culture 
supernatant resulting from the transfection. 
A recent method for measuring HBV virions directly in the supernatant of transfected cell 
culture without using radioactive elements has been established (Schittl, 2012). This method 
is characterized by its high sensitivity as it relies on the quantification of the purified 
genomes from immunoprecipitated mature HBV virions using a specific real time qPCR 
discriminating between genomic and plasmid DNA. Small amounts of virions can be 
detected by this technique as only 5% of normal virion production was sufficient to get a 
clear positive signal. Therefore, this assay seemed to be fitted for estimating the potential 
inhibition of aptamer AO-01 on HBV virion release. 
The results revealed a promising inhibition by the best binder AO-01 (at least 47%) in 
comparison with that of the negative aptamer AO-N (appr. 5.5%) (see Fig. 36). The number 
of MBD on the surface of one HBV capsid is probably between 90-120 MBDs. However, it 
is open whether almost all of the MBDs must be occupied by aptamers to block the capsid 
envelopment process or whether the binding of aptamers to some of these domains is 
sufficient for complete blocking of the envelopment process.  
In conclusion, this study marks the first one showing the successful selection of an aptamer 
(AO-01) having a high binding affinity (180 ± 82 nM) to the MBD of HBV capsid. 
Moreover, this aptamer (AO-01) is also considered to be the first one that could 
preliminarly inhibit the envelopment process of a virus (HBV) in cell culture. 
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7  Summary 
The hepatitis B virus (HBV) is a member of the family Hepadnaviridae. It causes human B-
type hepatitis. Its high prevelence and the large incidence for severe liver diseases in HBV 
infected individuals make HBV infection a major global health problem. HBV is a 
hepatotropic enveloped DNA virus consisting of a nucleocapsid and a surrounding envelope 
containing three surface proteins refered as small (S), middle (M) and large (L) protein. 
During the formation of hepatitis B virions a small domain of a viral L envelope protein 
(matrix domain, MD) interacts specifically with a binding domain (matrix binding domain, 
MBD) on the capsid surface. This interaction can be blocked by introducing point mutations 
in any of the both domains resulting in the blocking of capsid envelopment and consequently 
the abortion of virion release. The binding of an aptamer to the MBD with high affinity and 
specificity could be an approach to inhibit this interaction. This would open new possibilities 
in producing antiviral substances against HBV infection. 
In this project, specific aptamers for MBD on the HBV capsid surface were selected using in 
vitro selection with counter selection from an initial pool of 6×10
15
 different ssDNAs with a 25–
nt central block of randomized sequence. A wild type version of a C-terminally deleted HBV 
capsid protein C and an envelopment deficient point mutant C-I126A were overexpressed in 
E.coli. They assembled into capsids which were purified by size exclusion chromatography and 
sucrose gradient ultracentrifugation. Thirteen rounds of SELEX using the wild type capsids for 
positive selection and the I126A mutant capsids for counter selection were performed. Twelve 
aptamers (AO-01 to AO-12) were enriched within 73 sequenced clones. All twelve aptamers 
showed four conserved sequences (CG, CCA, TG & TG) which form a loop like structure in 
models for the fold of most of the oligonucleotides. Four out of twelve selected aptamers (AO-
01, AO-02, AO-03 and AO-04) represented more than 50% of all sequenced clones. Contrary to 
their dissociation constants (Kd) against mutant capsid, Kd values of these four aptamers against 
WT capsid showed direct correlation with their frequency.  
The aptamer AO-01 with the highest frequency (18 %) showed the lowest Kd against WT 
capsids (180 ± 82 nM). Its Kd value against the I126A mutant capsids was at least 7 fold 
higher (1306 ± 503 nM). The best binder AO-01 was proven to be specific for the MBD. Its 
binding affinity to WT capsids was 3.3-5.4 fold more than that to the I126A MBD point 
mutant capsids. Testing of the inhibitory potential of the best binder AO-01 on HBV release 
in transiently cotransfected HuH-7 cell revealed 47 % inhibition by AO-01 and no inhibition 
by an aptamer with random sequence AO-N. 
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8  Zusammenfassung 
Das Hepatitis B Virus (HBV) gehört zur Familie Hepadnaviridae. Es verursacht die Type B 
Hepatitis beim Menschen. Wegen seiner hohen Prävalenz und der hohen Inzidenz von 
schweren Lebererkrankungen in HBV-infizierten Personen stellt die HBV-Infektion ein 
bedeutendes globales Gesundheitsproblem dar. Das HBV ist ein hepatotrophes, umhülltes 
DNA-Virus, das aus einem Nukleokapsid und der umgebenden Hülle besteht, die drei 
Oberflächenproteine enthält, die als kleines (S), mittleres (M) und großes (L) Protein 
bezeichnet werden. Während der Bildung des Hepatitis B Virions interagiert eine kleine 
Domäne des viralen L Proteins (Matrix-Domäne, MD) spezifisch mit einer bindenden 
Domäne (Matrix-bindende Domäne, MBD) auf der Kapsidoberfläche. Diese Interaktion kann 
durch die Einführung von Punktmutationen in einer der beiden Domänen blockiert werden, 
was in einer Blockade der Kapsidumhüllung und daraufhin einer Inhibition der 
Virusfreisetzung resultiert. Die Bindung eines Aptamers an die MBD mit hoher Affinität und 
Spezifität könnte ein Ansatz sein, diese Interaktion zu inhibieren. Dies würde neue 
Möglichkeiten eröffnen, antivirale Substanzen gegen die HBV-Infektion zu entwickeln. 
In diesem Projekt wurden spezifische Aptamere gegen die MBD auf der HBV-
Kapsidoberfläche durch in vitro Selektion mit Gegenselektion von einem initialen Pool von 6 
x 10
15
 verschiedenen ssDNAs mit einem zentralen Block von 25 nt zufälliger Sequenz 
selektiert. Eine Wildtyp-Version eines C-terminal deletierten HBV-Kapsidproteins C und eine 
umhüllungsdefiziente Punktmutante C-I126A wurden in E. coli überexprimiert. Sie 
assemblierten zu Kapsiden und wurden durch Ausschlusschromatographie und 
Sucrosegradientenzentrifugaiton gereinigt. Dreizehn SELEX-Runden mit dem Wildtyp-
Kapsid für eine positive Selektion und der I126A-Mutante für die Gegenselektion wurden 
durchgeführt. Zwölf Aptamere (AO-01 bis AO-12) waren angereichert unter 73 sequenzierten 
Klonen. Alle zwölf Aptamere enthielten vier konservierte Sequenzen (CG, CCA, TG und 
TG), die eine schleifenartige Struktur in den Faltungsmodellen für die meisten 
Oligonukleotide bildeten. Vier der zwölf selektionierten Aptamere (AO-01, AO-02, AO-03 
und AO-04) repräsentierten mehr als 50 % aller sequenzierten Klone. Im Gegensatz zu den 
Dissoziationskonstanten (Kd) gegen das mutierte Kapsid, zeigten die Kd—Werte gegen das 
Wildtyp-Kapsid von diesen vier Aptameren eine Korrelation mit der Häufigkeit ihres 
Auftretens innerhalb der 73 sequenzierten Klone. 
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Das Aptamer AO-01 mit der höchsten Frequenz (18 %) zeigte den geringsten Kd—Werte 
gegen das Wildtyp-Kapsid (180 +/- 82 nM). Sein Kd—Wert gegen das I126A-mutierte Kapsid 
war mindestens 7-fach höher (1306 +/- 503 nM). Es wurde gezeigt, dass das Aptamer AO-01  
spezifisch an die MBD bindet. Seine Bindungsaffinität zu Wildtyp-Kapsiden war 3,3 – 5,4-
fach höher als zu der I126A MBD-Punktmutante des Kapsids. Die Bestimmung des 
inhibitorischen Potentials von AO-01 auf die Freisetzung des HBV in transient 
kotransfizierten HuH7-Zellen zeigte eine 47% Inhibition, aber keine Hemmung durch das 
Aptamer AO-N mit zufälliger Sequenz. 
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12 Appendix 
12.1 Nucleotide sequence encodes for delta-C WT core proteins 
Atggacattgacccttataaagaatttggagctactgtggagttactctcgtttttgccttc
tgacttctttccttccgtcagagatctcctagacaccgcctcagctctgtatcgagaagcct
tagagtctcctgagcattgctcacctcaccatactgcactcaggcaagccattctctgctgg
ggggaattgatgactctagctacctgggtgggtaataatttggaagatccagcatccaggga
tctagtagtcaattatgttaatactaacatgggtttaaagatcaggcaactattgtggtttc
atatatcttgccttacttttggaagagagactgtacttgaatatttggtctctttcggagtg
tggattcgcactcctccagcctatagaccaccaaatgcccctatcttatcaacacttccgga
aactactgttgtt (447 bp) 
12.2 Amino acid sequence of delta-C WT core proteins 
MDIDPYKEFGATVELLSFLPSDFFPSVRDLLDTASALYREALESPEHCSPHHTALRQAILCW
GELMTLATWVGNNLEDPASRDLVVNYVNTNMGLKIRQLLWFHISCLTFGRETVLEYLVSFGV
WIRTPPAYRPPNAPILSTLPETTVV (149 aa) 
12.3 Nucleotide sequence encodes for delta-C I126A mutant core proteins 
Atggacattgacccttataaagaatttggagctactgtggagttactctcgtttttgccttc
tgacttctttccttccgtcagagatctcctagacaccgcctcagctctgtatcgagaagcct
tagagtctcctgagcattgctcacctcaccatactgcactcaggcaagccattctctgctgg
ggggaattgatgactctagctacctgggtgggtaataatttggaagatccagcatccaggga
tctagtagtcaattatgttaatactaacatgggtttaaagatcaggcaactattgtggtttc
atatatcttgccttacttttggaagagagactgtacttgaatatttggtctctttcggagtg
tgggctcgcactcctccagcctatagaccaccaaatgcccctatcttatcaacacttccgga
aactactgttgtt (447 bp)  
12.4 Amino acid sequence of delta-C I126A mutant core proteins 
MDIDPYKEFGATVELLSFLPSDFFPSVRDLLDTASALYREALESPEHCSPHHTALRQAILCW
GELMTLATWVGNNLEDPASRDLVVNYVNTNMGLKIRQLLWFHISCLTFGRETVLEYLVSFGV
WARTPPAYRPPNAPILSTLPETTVV (149 aa) 
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